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 Transition-metal-catalyzed oxidative coupling reactions are important tools for the 
construction of carbon-carbon (C-C) and carbon-heteroatom (C-X) bonds from simple 
starting materials. A series of novel and synthetically useful reactions have been developed 
and are herein described. 
 Palladium-catalyzed chemoselective decarboxylative cross-coupling of benzoic 
acids with α-oxocarboxylic acids was realized via an arene sp2 C-H functionalization 
process. This work represents the first example of transition-metal-catalyzed cross-
coupling reactions with two acids acting in different roles. The synthetic utility of this 
method was confirmed by the synthesis of pitofenone, an antispasmodic used in the 
combined drug Spasmalgon. 
 A highly site-selective and diastereoselective fluorination of aliphatic amides via a 
palladium-catalyzed bidentate ligand-directed C−H bond functionalization process on 
unactivated sp3 carbons was developed. A wide variety of β-fluorinated amino acid 
derivatives and aliphatic amides, important motifs in medicinal and agricultural chemistry, 
were prepared with palladium acetate as the catalyst and selectfluor as the fluorine source.
x 
 
 The synthesis for cinnolines from N-phenylhydrazones was performed through an 
oxidation/cyclization sequence, representing the first copper-catalyzed coupling reaction 
of hydrazones through a C(sp3)-H bond functionalization process. The method provides 
an environmentally friendly and atom-efficient approach to biologically active cinnoline 
derivatives. 
 A novel rhodium-catalyzed imination of sulfoxides using O-(2,4-dinitrophenyl)-
hydroxylamine was developed under mild conditions with good functional group tolerance. 
The reaction provides an efficient access to free NH-sulfoximines, an important structural 





CHAPTER 1. INTRODUCTION 
 Construction of new carbon-carbon and carbon-heteroatom bonds is essential in 
organic chemistry. Traditionally, this process primarily relies on the use of 
prefunctionalized substrates, such as alkyl halides, triflates, boron or tin reagents. Despite 
its broad application in organic synthesis, the prefunctionalization of the starting materials 
usually requires additional synthetic steps, and thus reduces the overall efficiency of the 
approach. Moreover, in many cases, stoichiometric amounts of often toxic metal waste are 
generated in the process, which constitutes an environmental issue. As a promising tool for 
the efficient formation of C-C and C-X bonds, transition-metal-catalyzed direct 
functionalization of unreactive C-H bonds has emerged as a major topic of research in 
recent years. During the past decade, transition-metal-catalyzed direct C-H 
functionalization reactions have emerged as an essential topic in the field of organic 
synthetic methodology. Efficient and selective reactions of this type will definitely find 
widespread application in natural product research, material sciences, and pharmaceuticals. 
 In this dissertation, chapters 2-4 describe three novel transition-metal-catalyzed C-
H functionalization reactions that were developed during my graduate research. In chapter 






CHAPTER 2.  PALLADIUM-CATALYZED DIRECT ORTHO-ACYLATION OF 
BENZOIC ACIDS 
(Reproduced in part with permission from Miao, J.-M.; Ge, H.-B. “Palladium-Catalyzed 
Chemoselective Decarboxylative Ortho Acylation of Benzoic Acids with α‑Oxocarboxylic 





 2-Benzoylbenzoic acid derivatives are important intermediates for the synthesis of 
various bioactive compounds,1 and are often encountered as subunits of many biologically 
active compounds2 including natural products, pharmaceuticals, and agrochemical 
compounds. For example, balanol, a fungal metabolite produced by the fungus Verticillium 
 






balanoides and other fungi, is a potent inhibitor of protein kinase C (PKC);1j,k narceine, an 
opium alkaloid produced by the Papaver somniferum plant, is a bitter compound with 
narcotic effects;1i  pitofenone, the key ingredient in Spasmalgon (a combined drug), is an 
antispasmodic (Figure 2.1).1d Additionally, 2-benzoylbenzoic acids are often used as 
functional groups or substrates in photochemistry,3 chromatography4 and food chemistry.5  
 
Scheme 2.1 Synthesis of 2-Acylbenzoic Acids 
  
 Despite the demonstrated biological importance of 2-acylbenzoic acids, synthetic 
methods for these species are far from maturity. The most common routes start from 1,3-
isobenzofurandione derivatives and involve either a nucleophilic addition/elimination 
process by organometallic reagents6 or a Friedel-Crafts acylation process (Scheme 1.1).7 
In many cases, these reactions suffer severely from poor regioselectivity on the 
benzofurandione, and thus substituted 2-acylbenzoic acids are difficult to obtain in a 
satisfactory yield.6b,7c Therefore, the need for complementary, concise, and effective 
approaches to access these compounds is clear. On the basis of our success on direct ortho 
acylation of 2-phenylpyridines and acetanilides,8 we proposed that an efficient approach 





coupling of benzoic acids with α-oxocarboxylic acids by a Pd(II)-catalyzed C-H 
functionalization process (Scheme 2.1). 
 Transition-metal-catalyzed cross-coupling reactions remain one of the most 
powerful methods for carbon-carbon (C-C) bond formation.9 Among these methods, 
Pd(0)-catalyzed decarboxylative cross-coupling has recently attracted considerable 
attention due to the low cost, ready availability, and environmentally benign properties of 
carboxylic acids.10 Along with the well-studied benzoic acids, alkyl, alkenyl and alkynyl 
acids, α-oxocarboxylates, and oxalates have also been demonstrated as effective substrates, 
which enable the installation of a variety of functional groups on aromatic rings. 
Furthermore, since Crabtree first reported a direct decarboxylative cross-coupling of arenes 
with aromatic acids through a Pd(II)-catalyzed C-H functionalization process,11 the 
method has attracted considerable attention because the prefunctionalization of reaction 
substrates is avoided.12  
 As substrates, benzoic acids have been extensively studied in decarboxylative 
cross-coupling reactions by both Pd(0) and Pd(II) catalysis. It has been demonstrated that 
either a silver or copper source could effectively mediate the decarboxylation. On the other 
hand, from Yu’s studies, benzoic acid derivatives were fairly stable at high temperature 
(130 ˚C) in the presence of a catalytic amount of a Pd(II) source and an excess Ag(I) 
source.13 Moreover, α-oxocarboxylic acids, utilized in Goossen’s laboratory in Pd(0)-
catalyzed decarboxylative cross-couplings,14 have also been demonstrated as effective 
coupling partners in Pd(II) catalysis in our laboratory with either a silver or persulfate 





actanilides and 2-phenylpyridines, cyclic enamides16, O-methyl oximes17, 
phenylacetamides18, O-phenyl carbamates19, and 1-(pyrimidin-2-yl)-1H-indoles20 were 
also effective substrates for the direct decarboxylative acylation. These results support the 
feasibility of chemoselective decarboxylative cross-coupling of benzoic acids with α-
oxocarboxylic acids through Pd(II) catalysis under well-defined reaction conditions. It is 
noteworthy that, although the benzoic acid derivatives have been well studied as the 
substrates in metal-catalyzed C-H bond activation reactions,9 direct ortho-acylation of 
benzoic acids remains a challenge. Furthermore, transition-metal-catalyzed cross-coupling 
of two carboxylic acids with different roles in the reaction has not been reported. As part 
of our program to develop novel transition-metal-catalyzed cross-coupling reactions with 
diverse substrates,8,15,21 we have developed the synthesis of 2-acylbenzoic acid derivatives 
through chemoselective decarboxylative cross-coupling of benzoic acids with α-
oxocarboxylic acids via a palladium-catalyzed C-H bond functionalization process. 
 
2.2 Results and Discussion 
 Considering that an α-oxocarboxylic acid is a potential source of benzoic acid 
through decarboxylation and oxidation, 2-methylbenzoic acid was chosen as the substrate 
for the decarboxylative cross-coupling reaction with α-oxocarboxylic acid in the presence 
of a catalytic amount of Pd(TFA)2 and an excess amount of Ag2CO3 as the oxidant and the 
decarboxylation reagent on the basis of our previous reports.8,21 After an extensive solvent 
screening, DME and dioxane were shown to be optimal solvents for this coupling, 
providing the desired product in moderate yields (Table 2.1, entries 4 and 5). The following 










Oxidant (equiv) Solvents (mL) Yield (%)b 
1 Pd(TFA)2 Ag2CO3 (2.0) DMF trace 
2 Pd(TFA)2 Ag2CO3 (2.0) THF trace 
3 Pd(TFA)2 Ag2CO3 (2.0) tBuOH 32 
4 Pd(TFA)2 Ag2CO3 (2.0) dioxane 55 
5 Pd(TFA)2 Ag2CO3 (2.0) DME 58 
6 PdCl2(PhCN)2 Ag2CO3 (2.0) DME trace 
7 PdCl2(MeCN)2 Ag2CO3 (2.0) DME 41 
8 Pd(OAc)2 Ag2CO3 (2.0) DME 48 
9 Pd(TFA)2 Ag2O (2.0) DME 20 
10 Pd(TFA)2 AgOAc (2.0) DME 38 
11 Pd(TFA)2 (NH4)2S2O8 (2.0) DME 0 
12c Pd(TFA)2 Ag2CO3 (2.0) DME 60 
13 Pd(TFA)2 Ag2CO3 (3.0) DME 64 
14d Pd(TFA)2 Ag2CO3 (3.0) DME 80 
15 Pd(TFA)2 Ag2CO3 (3.0) DME 56 
16d Pd(TFA)2 Ag2CO3 (3.0) dioxane 67 
a Conditions: 1a (0.2 mmol), Pd source, oxidants, 2a (0.6 mmol), 2 mL of solvent, 120 ˚C, 
24 h unless otherwise noted. b Isolated yields. c 48 h.  d At 150 ˚C. 
 
catalyze this reaction, Pd(TFA)2 is more effective (entries 7 and 8). A further survey of 
oxidants showed that silver carbonate was the best choice. Due to our success in the 
decarboxylation of α-oxocarboxylic acids with a persulfate salt8, replacement of Ag2CO3 





persulfate salts led to the decarboxylation of both acids and no desired product was 
obtained (entry 11). Further optimization of reaction conditions showed that although 
increasing the reaction time had no apparent effect on this reaction, the yield was 
significantly improved by increasing the amount of Ag2CO3 and raising the reaction 
temperature (entries 12-14). It was also noted that the coupling product could be obtained 
either with less Pd catalyst or when dioxane was used as the solvent, albeit in lower yields 
(entries 15 and 16). 
 
Scheme 2.2 Substrate Scope of Benzoic Acidsa,b. a Conditions: 2.1 (0.2 mmol), Pd(TFA)2 
(0.02 mmol), 2.2a (0.6 mmol), Ag2CO3 (0.6 mmol), 2 mL of DME, 150 ˚C, 24 h unless 
otherwise noted.  b Isolated yields. c 165 °C. d 130 °C. e 48 h. 
  
 With the optimized reaction conditions in hand, we then carried out the substrate 





compatible with electron-donating and electron-withdrawing groups substituting the 
benzoic acids (2.3a-j), while substrates containing electron-donating groups provided 
higher yields than their electron-withdrawing counterparts, with the exception of 2.3e. As 
expected, halogens (F, Cl, and Br) were tolerated under the current reaction system, 
allowing the further manipulation of the initial products. Furthermore, good yields were 
also observed with disubstituted benzoic acids (2.3k,l). 
 
Scheme 2.3 Substrate Scope of α-Oxocarboxylic Acidsa,b. a Conditions: 2.1b (0.2 mmol), 
Pd(TFA)2 (0.02 mmol), 2.2 (0.6 mmol), Ag2CO3 (0.6 mmol), 2 mL of DME, 150 ˚C, 24 h 
unless otherwise noted.  b Isolated yields. c 165 °C. d 130 °C. e 48 h. f Ag2CO3 (0.5 mmol). 
 
 Next, a substrate scope study for the α-oxocarboxylic acids was carried out. As 
shown in Scheme 2.3, electron-rich groups (MeO and Me), and halogens (F, Cl, and Br) 





electron-withdrawing groups are not well tolerated in the current reaction system. As 
observed in our previous studies,8 there is not significant steric effect with these substrates 
(2.3n,o). In contrast, there is a clear electronic effect. Furthermore, the sterically hindered 
substrate 2,4,6-trimethylbenzoylformic acid also provided the desired product 2.3x in high 
yield. 
 On the basis of the reports from Yu13,22 and our laboratory8,21, a decarboxylative 
cross-coupling reaction mechanism is proposed (Scheme 2.4). It is believed that this 
transformation starts with the palladation of silver benzoate 2.A into the Pd(II) intermediate 
2.B, which then undergoes a transmetalation step with the acylsilver species 2.C formed 
by the silver-mediated decarboxylation of 2.2, to generate the Pd(II) intermediate 2.D. 
Reductive elimination of 2.D provides the silver salt 2.E and Pd(0), which will be 
reoxidized into Pd(II) by Ag2CO3. Protonation of intermediate 2.E provides the desired 
product 2.3. 
 






 To demonstrate the synthetic utility of this method, it was applied to the synthesis 
of pitofenone (Scheme 2.5). Pd(II)-catalyzed direct decarboxylative ortho acylation of 
benzoic acid with (4-fluorobenzoyl)formic acid provided 2-(4-fluorobenzoyl)benzoic acid 
(2.3t) in 62% yield. Nucleophilic substitution of 2.3t by 1-(2-hydroxyethyl)piperidine, 
followed by methylation, produced pitofenone in 91% yield over the two steps. It is 
noteworthy that this route also allows the installation of extra substituents on the phenyl 
rings, which facilitates the medicinal chemistry study of this compound. 
 
Scheme 2.5 Synthesis of Pitofenone 
 
2.3 Summary 
 In summary, an efficient decarboxylative cross-coupling reaction of benzoic acids 
with α-oxocarboxylic acids has been developed via a palladium-catalyzed C-H bond 
functionalization process. This transformation is the first example of direct ortho-acylation 
of benzoic acids. The method provides an efficient access to 2-acylbenzoic acid derivatives. 
Furthermore, the synthesis of pitofenone was also achieved by employing this 






provides a more efficient approach to access this compound. In addition, this route also 
enables the systematic medicinal chemistry study of this compound, which could not be 
easily achieved by the current methods. 
 
2.4 Experimental 
 General Methods. All the solvents and commercially available reagents were 
purchased from commercial sources and used directly. For TLC analysis, precoated plates 
(w/h F254, Dynamic Adsorbents Inc, 0.25 mm thick) were used; for air-flashed column 
chromatography, Flash Silica Gel (Dynamic Adsorbents Inc, 32-63 μm) was used. The 1H 
and 13C NMR spectra were obtained on a Bruker 500 MHz NMR Fourier transform 
spectrometer. 1H NMR data was reported as: chemical shift (δ ppm), multiplicity, coupling 
constant (Hz), and integration. 13C NMR data was reported in terms of chemical shift (δ 
ppm), multiplicity, and coupling constant (Hz). The infrared spectra were obtained using a 
Thermo Nicolet IR 330 Spectrometer. High Resolution Mass (MS) analysis was obtained 
using MAT-95 series GC-MS system with Electrospray Ionization (ESI). 
 Preparation of Starting Materials: 
 Benzoic acids (2.1a-m) and α-oxocarboxylic acids (2.2a, 2.2n, 2.2q and 2.2r) were 
purchased from Sigma-Aldrich, TCI, Alfa Aesar or Acros. Other α-oxocarboxylic acids 







Scheme 2.6 Starting Materials for Acylation 
 
 General procedure for the decarboxylative acylation recations. A 20 mL oven-
dried pressure tube was charged with benzoic acid (2.1, 0.2 mmol), α-oxocarboxylic acid 
(2.2, 0.6 mmol), Pd(TFA)2 (6.6 mg, 0.02 mmol), Ag2CO3 (0.5-0.6 mmol), and DME (2.0 
mL). The tube was then sealed and stirred vigorously at 150-165 ˚C for 24-48 h. After 
cooling to room temperature, the reaction mixture was diluted with EtOAc, filtered through 






by flash chromatography on silica gel (gradient elution with 1% AcOH and 8 to 15% 
EtOAc in hexanes, v/v) to yield the desired product 2.3. 
 2-Benzoyl-6-methylbenzoic acid (2.3a). White solid, yield: 80% (150 °C, 24 h, 
known compound2). 1H NMR (500 MHz, CDCl3) δ: 2.62 (s, 3H), 7.28-7.31 (m, 2H), 
7.37-7.39 (m, 3H), 7.48 (t, J = 7.6 Hz, 1H), 7.60-7.61 (m, 2H); MS (ESI): m/z = 239.1, 
[M - H+]. 
 2-Benzoyl-6-chlorobenzoic acid (2.3b). White solid, yield: 51% (150 °C, 12 h, 
known compound3). 1H NMR (500 MHz, DMSO) δ: 7.42-7.45 (m, 2H), 7.52-7.56 (m, 
4H), 7.78-7.80 (m, 2H), 13.27 (br s, 1H); MS (ESI): m/z = 259.0, [M - H+]. 
 2-Benzoyl-5-methoxybenzoic acid (2.3c). White solid, yield: 70% (150 °C, 24 h, 
known compound4). 1H NMR (500 MHz, CDCl3) δ: 3.88 (s, 3H), 7.11 (dd, J = 2.6, 8.5 
Hz, 1H), 7.33 (d, J = 8.5 Hz, 1H), 7.38 (t, J = 7.8 Hz, 2H), 7.48-7.52 (m, 2H), 7.69 (d, J = 
8.5 Hz, 2H), 10.04 (br s, 1H); MS (ESI): m/z = 255.1 [M - H+]. 
 2-Benzoyl-5-methylbenzoic acid (2.3d). White solid, yield: 85% (165 °C, 24 h, 
known compound2). 1H NMR (500 MHz, CDCl3) δ: 2.45 (s, 3H), 7.26 (d, J = 7.3 Hz, 
1H), 7.38 (t, J = 7.8 Hz, 2H), 7.44 (dd, J = 0.7, 7.8 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 7.69 
(dd, J = 0.7, 7.4 Hz, 2H), 7.85 (s, 1H), 11.02 (br s, 1H); MS (ESI): m/z = 239.1, [M - 
H+]. 
 2-Benzoyl-5-fluorobenzoic acid (2.3e). White solid, yield: 80% (150 °C, 24 h, 
known compound5). 1H NMR (500 MHz, CDCl3) δ: 7.34-7.45 (m, 4H), 7.56 (t, J = 7.4 
Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.75 (dd, J = 2.3, 8.9 Hz, 1H); MS (ESI): m/z = 243.3 






 2-Benzoyl-5-bromobenzoic acid (2.3f). White solid, yield: 63% (130 °C, 24 h, 
known compound6). 1H NMR (500 MHz, CDCl3) δ: 7.26 (d, J = 8.0 Hz, 1H), 7.42 (t, J = 
7.5 Hz, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.69-7.71 (m, 2H), 7.79 (dd, J = 2.0, 8.0 Hz, 1H), 
8.21 (d, J = 2.0 Hz, 1H); MS (ESI): m/z = 303.0 [M - H+]. 
 2-Benzoyl-5-chlorobenzoic acid (2.3g). White solid, yield: 71% (150 °C, 24 h, 
known compound5). 1H NMR (500 MHz, CDCl3) δ: 7.32 (d, J = 8.2 Hz, 1H), 7.41 (t, J = 
7.8 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.63 (dd, J = 2.0, 8.2 Hz, 1H), 7.69 (d, J =7.3 Hz, 
2H), 8.03 (d, J = 2.0 Hz, 1H), 10.03 (br s, 1H); MS (ESI): m/z = 259.0 [M - H+]. 
 2-Benzoyl-4-methylbenzoic acid (2.3h). White solid, yield: 75% (150 °C, 48 h, 
known compound1). 1H NMR (500 MHz, DMSO) δ: 2.41 (s, 3H), 7.22 (s, 1H), 7.45-7.51 
(m, 3H), 7.60-7.63 (m, 3H), 7.90 (d, J = 8.0 Hz, 1H), 13.00 (br s, 1H); MS (ESI): m/z = 
239.3 [M - H+]. 
 2-Benzoyl-4-chlorobenzoic acid (2.3i). Pale yellow solid, yield: 58% (150 °C, 24 
h, known compound7). 1H NMR (500 MHz, CDCl3) δ: 7.34 (d, J = 2.0 Hz, 1H), 7.42 (t, J 
= 7.5 Hz, 2H), 7.51-7.57 (m, 2H), 7.69 (d, J = 7.5 Hz, 2H), 8.01 (d, J = 8.4 Hz, 1H), 
10.14 (br s, 1H); MS (ESI): m/z = 259.0 [M - H+]. 
 2-Benzoyl-4-(trifluoromethyl)benzoic acid (2.3j). White solid, yield: 56% 
(165 °C, 48 h, known compound8). 1H NMR (500 MHz, CDCl3) δ: 7.44 (t, J = 7.5 Hz, 
2H), 7.58 (t, J = 7.5 Hz, 1H), 7.64 (s, 1H), 7.70 (d, J = 7.5 Hz, 2H), 7.83 (d, J = 8.0 Hz, 
1H), 8.18 (d, J = 8.0 Hz, 1H); MS (ESI): m/z = 293.3 [M - H+]. 
 2-Benzoyl-4,6-dimethylbenzoic acid (2.3k). White solid, yield: 81% (165 °C, 24 






1H), 7.11 (s, 1H), 7.38-7.40 (m, 3H), 7.60-7.62 (m, 2H); MS (ESI): m/z = 253.2 [M - 
H+]. 
 2-Benzoyl-3,6-dimethylbenzoic acid (2.3l). White solid, yield: 74% (150 °C, 24 
h, known compound10). 1H NMR (500 MHz, CDCl3) δ: 2.12 (s, 3H), 2.40 (s, 3H), 7.29 (s, 
1H), 7.39 (t, J = 7.8 Hz, 2H), 7.51 (t, J = 7.5 Hz, 1H), 7.68 (d, J = 7.5 Hz, 2H), 7.74 (s, 
1H), 10.73 (br s, 1H); MS (ESI): m/z = 253.2 [M - H+]. 
 2-(2-Methylbenzoyl)benzoic acid (2.3m). White solid, yield: 70% (150 °C, 24 h, 
known compound11). 1H NMR (500 MHz, CDCl3) δ: 2.61 (s, 3H), 7.09 (d, J = 7.5 Hz, 
1H), 7.15 (dd, J = 1.0, 7.7 Hz, 1H), 7.23-7.27 (m, 1H), 7.35 (dt, J = 1.4, 7.5 Hz, 1H), 7.43 
(dd, J = 0.9, 7.5 Hz, 1H), 7.55 (dt, J = 1.2, 7.6 Hz, 1H), 7.65 (dt, J = 1.2, 7.6 Hz, 1H), 
8.10 (dd, J = 0.9, 7.8 Hz, 1H), 9.64 (br s, 1H); MS (ESI): m/z = 239.1 [M - H+]. 
 2-(2-Fluorobenzoyl)benzoic acid (2.3n). White solid, yield: 62% (165°C, 24 h, 
known compound5). 1H NMR (500 MHz, CDCl3) δ: 7.02-7.06 (m, 1H), 7.21 (t, J = 7.6 
Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.48-7.52 (m, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.65 (t, J = 
7.6 Hz, 1H), 7.80 (dt, J = 1.7, 7.6 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 10.82 (br s, 1H); MS 
(ESI): m/z = 243.3 [M - H+]. 
 2-(2-Bromobenzoyl)benzoic acid (2.3o). White solid, yield: 63% (130 °C, 24 h, 
known compound5). 1H NMR (500 MHz, CDCl3) δ: 7.29-7.32 (m, 2H), 7.38-7.41 (m, 
1H), 7.46 (dd, J = 1.0, 7.4 Hz, 1H), 7.57-7.67 (m, 3H), 7.99 (d, J = 7.4 Hz, 1H); MS 
(ESI): m/z = 303.0 [M - H+]. 
 2-(3-Methylbenzoyl)benzoic acid (2.3p). White solid, yield: 61% (150 °C, 24 h, 






7.33-7.35 (m, 2H), 7.45 (d, J = 7.7 Hz, 1H), 7.53-7.56 (m, 2H), 7.64 (dt, J = 1.2, 7.5 Hz, 
1H), 8.06 (d, J = 7.7 Hz, 1H), 11.03 (br s, 1H); MS (ESI): m/z = 239.1 [M - H+]. 
 2-(3-Chlorobenzoyl)benzoic acid (2.3q). Pale yellow solid, yield: 51% (150 °C, 
24 h, known compound7). 1H NMR (500 MHz, CDCl3) δ: 7.33-7.37 (m, 2H), 7.49-7.51 
(m, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.59 (dt, J = 1.2, 7.8 Hz, 1H), 7.67-7.71 (m, 2H), 8.09 
(d, J = 7.8 Hz, 1H); MS (ESI): m/z = 259.0 [M - H+]. 
 2-(4-Methoxybenzoyl)benzoic acid (2.3r). White solid, yield: 74% (165 °C, 48 
h, known compound12). 1H NMR (500 MHz, CDCl3) δ: 3.85 (s, 3H), 6.89 (d, J = 8.9 Hz, 
2H), 7.36 (d, J = 7.5 Hz, 1H), 7.56 (dt, J = 1.1, 7.7 Hz, 1H), 7.65 (dt, J = 1.1, 7.5 Hz, 
1H), 7.70-7.72 (m, 2H), 8.10 (d, J = 7.8 Hz, 1H); MS (ESI): m/z = 255.1 [M - H+]. 
 2-(4-Methylbenzoyl)benzoic acid (2.3s). White solid, yield: 75% (165 °C, 24 h, 
known compound12). 1H NMR (500 MHz, CDCl3) δ: 2.39 (s, 3H), 7.20 (d, J = 8.0 Hz, 
2H), 7.34 (dd, J = 0.9, 7.5 Hz, 1H), 7.54 (dt, J = 1.2, 7.5 Hz, 1H), 7.59-7.65 (m, 3H), 8.06 
(dd, J = 0.9, 7.8 Hz, 1H), 8.44 (br s, 1H); MS (ESI): m/z = 239.2 [M - H+]. 
 2-(4-Fluorobenzoyl)benzoic acid (2.3t). White solid, yield: 62% (150 °C, 24 h, 
known compound5). 1H NMR (500 MHz, CDCl3) δ: 7.05 (t, J = 8.6 Hz, 2H), 7.34 (d, J = 
7.2 Hz, 1H), 7.55 (dt, J = 1.0, 7.6 Hz, 1H), 7.64 (dt, J = 1.0, 7.6 Hz, 1H), 7.69-7.72 (m, 
2H), 8.04 (d, J = 7.7 Hz, 1H), 11.47 (br s, 1H); MS (ESI): m/z = 243.2 [M - H+]. 
 2-(4-Chlorobenzoyl)benzoic acid (2.3u). Pale yellow solid, yield: 56% (150 °C, 
24 h, known compound12). 1H NMR (500 MHz, CDCl3) δ: 7.35-7.39 (m, 3H), 7.58 (dt, J 
= 0.8, 7.7 Hz, 1H), 7.63-7.67 (m, 3H), 8.08 (d, J = 7.8 Hz, 1H), 9.85 (br s, 1H); MS 






 2-(4-Bromobenzoyl)benzoic acid (2.3v). White solid, yield: 55% (130 °C, 24 h, 
known compound13). 1H NMR (500 MHz, CDCl3) δ: 7.36 (d, J = 7.5 Hz, 1H), 7.54-7.60 
(m, 5H), 7.68 (t, J = 7.4 Hz, 1H), 8.09 (d, J = 7.8 Hz, 1H); MS (ESI): m/z = 303.0 [M + 
H+]. 
 2-(2,4-Dimethylbenzoyl)benzoic acid (2.3w). White solid, yield: 80% (165 °C, 
48 h, known compound14). 1H NMR (500 MHz, CDCl3) δ: 2.33 (s, 3H), 2.60 (s, 3H), 6.89 
(d, J = 7.9 Hz, 1H), 7.05- 7.08 (m, 2H), 7.40 (dd, J = 0.8, 7.5 Hz, 1H), 7.54 (dt, J = 1.2, 
7.5 Hz, 1H), 7.63 (dt, J = 1.2, 7.5 Hz, 1H), 8.02 (dd, J = 0.9, 7.8 Hz, 1H), 8.70 (br s, 1H). 
MS (ESI): m/z = 253.3 [M - H+]. 
 2-(2,4,6-Trimethylbenzoyl)benzoic acid (2.3x). White solid, yield: 82% 
(165 °C, 48 h, known compound13). 1H NMR (500 MHz, CDCl3) δ: 2.16 (s, 6H), 2.32 (s, 
3H), 6.89 (s, 2H), 7.38 (d, J = 7.5 Hz, 1H), 7.46 (t, J = 1.2, 7.5 Hz, 1H), 7.59 (dt, J = 0.8, 
7.5 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 9.76 (br s, 1H); MS (ESI): m/z = 267.3 [M - H+]. 
 Procedure for the synthesis of pitofenone. To a suspension of NaH (60%, 32 mg, 
0.8 mmol) in dry THF was added 1-(2-hydroxyethyl)piperidine (85 μL, 0.6 mmol) at room 
temperature. Then the mixture was refluxed for 30 min. After cooled to room temperature, 
the mixture was slowly added a suspension of 3u (73mg, 0.3 mmol) and NaH (60%, 20mg, 
0.5 mmol) in dry THF at room temperature. The resulting reaction mixture was stirred 
overnight, and then quenched with MeOH. Next, 1M HCl was added to adjust the pH to 2, 
and the solvent was removed under vacuo. The residue was dissolved with anhydrous 
MeOH (3 mL), and cooled to 0 °C. To this solution was slowly added SOCl2 (280 uL) at 
0 °C, and then warmed to room temperature. The reaction mixture was stirred at room 






solvent was evaporated under vacuo, and the residue was dissolved with 1N NaOH, and 
extracted with DCM (3 x 10 mL). The organic layer was combined and washed with water, 
brine, and dried over anhydrous Na2SO4. After removal of the solvent, the residue was 
purified with flash chromatography (gradient eluent of 1% Et3N and 50% EtOAc in 
hexanes, v/v) to give 100 mg of the desired compound pitofenone as a pale yellow oil. 
 Methyl 2-(4-(2-(piperidin-1-yl)ethoxy)benzoyl)benzoate (pitofenone, 2.4). Pale 
yellow solid, yield: 91% (from 3u). 1H NMR (500 MHz, CDCl3) δ: 1.42-1.46 (m, 2H), 
1.57-1.61 (m, 4H), 2.49 (br s, 4H), 2.77 (t, J = 6.0 Hz, 2H), 3.63 (s, 3H), 4.14 (t, J = 6.0 
Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 7.37 (dd, J = 1.1, 7.5 Hz, 1H), 7.54 (dt, J = 1.3, 7.5 Hz, 
1H), 7.61 (dt, J = 1.3, 7.5 Hz, 1H), 7.71 (d, J = 9.0 Hz, 2H), 8.04 (dd, J = 1.0, 7.5 Hz, 
1H). 13C NMR (125 MHz, CDCl3) δ: 24.2, 26.0, 52.2, 55.1, 57.7, 66.3, 114.3, 127.7, 
129.1, 129.3, 130.1, 130.2, 131.6, 132.3, 142.1, 162.9, 166.5, 195.8. IR (neat) ν 3067, 
2934, 2852, 2786, 1916, 1726, 1666, 1560, 1576, 1508, 1281, 1255 cm-1; Ms (ESI): m/z 
= 368.3 [M + H+]. 
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CHAPTER 3. PALLADIUM-CATALYZED SITE-SELECTIVE FLUORINATION OF 
UNACTIVATED SP3 C-H BONDS 
(Reproduced in part with permission from Miao, J.-M.; Yang, K.; Kurek, M.; Ge, H.-B. 
“Palladium-Catalyzed Site-Selective Fluorination of Unactivated C(sp3)−H Bonds”, Org. 





 Fluorine substitution is of great interest in the fields of medicinal chemistry, 
agricultural chemistry, and material science.1 Fluorination affects nearly all physical and 
chemical properties including stability, solubility, lipophilicity, conformation, and 
bioavailability compared to the parent molecules.2 It has been estimated that fluorine-
containing molecules account for about 25% of all pharmaceuticals and 30-40% of 
agrochemicals, including three of the top five best-selling drugs in 2013.3 Furthermore, the 
importance of fluorine in medical imaging technologies has also been demonstrated.4 
Therefore, the discovery of selective incorporation methods for fluorine atoms into 
biologically relevant organic molecules has been an active research area in organic 
chemistry over the past 40 years.5 
 Transition metal-catalyzed C−H functionalization has been extensively studied in 






compared to the classical approaches.6 Within this reaction class, site-selective direct  
fluorination of aromatic C−H bonds has been documented recently via a palladium or 
copper catalysis.7 Despite a challenging process, transition metal-catalyzed direct 
fluorination of sp3 carbons has also been established.8 Copper,9  iron,10  manganese,11 
palladium,12 silver,13 and vanadium14 have all been demonstrated as effective catalysts in 
this process. However, current studies on unactivated sp3 C−H bonds suffer from low to 
moderate site-selectivity. In addition, fluorination on C−H bonds of the relatively reactive 
benzylic or allylic sp3 carbons is typically favored over that on unactivated sp3 bonds, 
which limits the potential applications of this approach. Inspired by the Pd-catalyzed 
ligand-directed C−H functionalization of unactivated β-sp3 carbons of amides,15 we have 
investigated the direct site-selective fluorination of α-amino acid derivatives and aliphatic 
amides via palladium catalysis with the assistance of a bidentate directing group.  
 
3.2 Results and Discussion 
 Fluorinated amino acids have attracted considerable attention in the past decades 
due to the importance of these compounds in medicinal chemistry research.16 Current 
synthetic methods of these molecules primarily rely on the nucleophilic substitution 
reaction, which requires pre-installation of a functional group to the C−H bonds.17 In order 
to provide a direct synthetic approach for fluorinating unactivated sp3 carbons, we began 
our investigation on palladium-catalyzed fluorination of amino acid derivatives with the 
assistance of a bidentate ligand. Although 8-aminoquinoline has been widely used as a 
directing group for transition metal-catalyzed C−H functionalization, electrophilic 






fluorine reagent. Therefore, 2-(pyridin-2-yl)isopropyl amine18 was chosen as the directing 
group for fluorination of the 2-aminobutyric acid derivative 3.1a (Scheme 1). Initial studies 
showed that the desired β-fluorinated product 3.2a  could be obtained with 1-chloromethyl-
4-fluoro-1,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate) (Selectfluor) as the 
fluorinating reagent in dichloroethane (entry 1).  To our delight, the reaction yield was 
significantly improved with the addition of AgOAc or Ag2CO3 (entries 3 and 4). Next, an 
extensive solvent screening was carried out, and the mixture of dichloroethane and 
isobutyronitrile proved to be optimal, providing 3.2a in 38% yield (entry 11). Further 
screening of the palladium catalysts showed that Pd(OAc)2 is optimal although several 
other catalysts could also provide the desired product (entries 13-15). Interestingly, the 
addition of Mn(OAc)2 or Fe(OAc)2  significantly improved the reaction yield, with 0.3 
equivalents of Fe(OAc)2 giving the best result (entries 16-18). As we expected, this reaction 
showed a high site-selectivity by favoring β-C−H bonds due to the preference of the 
formation of a five-membered ring intermediate in the cyclopalladation step. Delightfully, 
a high diastereoselectivity was also observed by favoring the anti diastereoisomer. It is 
noteworthy that only low to moderate diastereoselectivities have been reported in previous 
Pd-catalyzed sp3 C−H functionalization of linear aliphatic α-amino acids with relatively 
small functional groups, such as Me15g, OMe17a, and Oac19. It should be mentioned that 
under the optimized conditions, 2-(1,3-dioxoisoindolin-2-yl)-N-(quinolin-8-yl)butanamide 









Table 3.1 Optimization of Reaction Conditions for Fluorinationa 
 
Entry Pd Source 
(10 mol %) 
Additive (equiv) Solvents (mL) Yield (%)b 
1 Pd(OAc)2 - DCE (3.0) trace 
2 Pd(OAc)2 AgNO3 (2.0) DCE (3.0) trace 
3 Pd(OAc)2 AgOAc (2.0) DCE (3.0) 21 
4 Pd(OAc)2 Ag2CO3 (2.0) DCE (3.0) 25 
5 Pd(OAc)2 Na2CO3 (2.0) DCE (3.0) - 
6 Pd(OAc)2 K2CO3 (2.0) DCE (3.0) - 
7 Pd(OAc)2 Ag2CO3 (2.0) MeCN (3.0) - 
8 Pd(OAc)2 Ag2CO3 (2.0) DME (3.0) 18 
9 Pd(OAc)2 Ag2CO3 (2.0) chloroform (3.0) 5 
10 Pd(OAc)2 Ag2CO3 (2.0) DCE (3.0)/MeCN (0.3) 31 
11 Pd(OAc)2 Ag2CO3 (2.0) DCE (3.0)/iPrCN (0.3) 38 
12 Pd(OAc)2 Ag2CO3 (2.0) DCE (3.0)/tBuCN (0.3) 33 
13 Pd(TFA)2 Ag2CO3 (2.0) DCE (3.0)/iPrCN (0.3) 29 
14 Pd(acac)2 Ag2CO3 (2.0) DCE (3.0)/iPrCN (0.3) 12 

















20 Pd(OAc)2 Fe(OAc)2 (0.3) DMF 27 
a Reaction conditions: 3.1a (0.30 mmol), Pd source (10 mol %), F source (2.5 equiv), 
Ag2CO3 (2.0 equiv), additive, solvent, 150 C, air, 14 h. b Yields are based on 3.1a, 







Scheme 3.1 Scope of Amino Acid Derivativesa,b. a Reaction conditions: 3.1 (0.30 mmol), 
Pd(OAc)2 (10 mol %), Selectfluor (2.5 equiv), Ag2CO3 (2.0 equiv), Fe(OAc)2 (0.3 equiv), 
iPrCN (300 µL), 3.0 mL DCE, 150 C, air, 14 h. b Isolated yields. c 0.25 equiv of Fe(OAc)2. 
d Without Fe(OAc)2. PIP = 2-(pyridin-2-yl)isopropyl. 
 
 With optimized conditions in hand, the scope of amino acids was studied (Scheme 
3.1). As expected, good yields were obtained with linear aliphatic amino acid derivatives 
with high diastereoselectivities (3.2a-e). In addition, the cyclic amino acid derivative 3.1f 
was an effective substrate, affording the desired product 3.2f in 82% yield. Moreover, a 
predominant preference of functionalizing β-C−H bonds over the relatively reactive 
benzylic γ-C−H bonds was also observed (3.2d), distinguishing this process from the 
current direct fluorination methods which favor the benzylic C−H bonds. Furthermore, 






corresponding β-fluorinated amino acid derivatives in good yields with excellent 
diastereoselectivities (3.2g-l).  
 Additionally, the structure and absolute configuration of the phenylalanine 
derivative L-3.2g (CCDC no. 1052086) were confirmed with X-ray analysis (Figure 3.1). 
                          
Figure 3.1 X-Ray crystal structure of L-3.2g 
 
 Next, substrate scope study of non-amino acid aliphatic amides was carried out. As 
shown in Scheme 3.2, both linear and α-branched aliphatic amides afforded the desired 
products in good yields under modified reaction conditions (3.4a-l). Similarly, 
functionalization of β-C−H bonds was favored over the relatively reactive benzylic γ- or 
δ-C−H bonds (3.4d and 3.4e). As expected, high diastereoselectivity was also observed 
with α-branched aliphatic amides (3.4g-l). Furthermore, it was found that the current 
process favored functionalization of β-C−H bonds of the sp3 carbons over γ-C−H bonds of 
the sp2 carbons, indicating that formation of a five-membered ring intermediate is preferred 






Scheme 3.2 Scope of Aliphatic Amidesa,b. a Reaction conditions: 3.3 (0.30 mmol), 
Pd(OAc)2 (10 mol %), Selectfluor (2.5 equiv), Ag2CO3 (2.0 equiv), Fe(OAc)2 (0.75 equiv), 
MeCN (400 µL), 3.0 mL DCE, 150 C, air, 14 h. b Isolated yields. c 3.0 equiv Selectfluor. 
d 0.2 equiv Fe(OAc)2. e No Fe(OAc)2. f 0.5 equiv Fe(OAc)2. PIP = 2-(pyridin-2-yl)isopropyl. 
 
 To further demonstrate the synthetic utility of this fluorination method, removal of 
the protecting and the directing group PIP was carried out, and the corresponding products 
were obtained in good yields (Scheme 3.3). 
 






  In addition, no apparent epimerization of the α-chiral center was observed during 
the fluorination of the D-2-(1,3-dioxoisoindolin-2-yl)-3-phenyl-N-(2-(pyridin-2-
yl)propan-2-yl)propanamide (D-1g) (Scheme 3.4). 
 
Scheme 3.4 Synthesis of D-3.2g 
 
 On the basis of the above obtained results and the previous reports,7,12b,20 a plausible 
reaction mechanism is proposed (Scheme 3.5). Coordination of amide 3.1 or 3.3 to a 
palladium species followed by a base-promoted ligand exchange process in the presence 
of MeCN or iPrCN produces the palladium complex 3.A. Subsequently, cyclometalation 
of the palladium complex 3.A occurs to generate the intermediate 3.B via a C−H bond 
activation process. Oxidative addition of the intermediate 3.B with Selectfluor provides the 
palladium (IV) species 3.C, which then gives rise to the final product 3.2 or 3.4 via 
reductive elimination followed by ligand dissociation.21 Although the exact role of Ag2CO3 
in the reaction is not clear, it is believed that this species participates in the ligand exchange 
and subsequent C−H bond cleavage steps by acting as a base, and also possibly promotes 
the oxidative addition of Selectfluor to the intermediate 3.B. On the other hand, the role of 










Scheme 3.5 Proposed Catalytic Cycle for β–Fluorination 
 
3.3 Summary 
 In summary, the palladium-catalyzed, ligand-directed, highly site-selective 
fluorination of amino acid derivatives and aliphatic amides was developed via an sp3 C−H 
bond functionalization process. This reaction featues good diastereoselectivity and 
functional group compatibility. Additionally, a great preference for functionalizing the 
C−H bonds of β-sp3 carbons over those of relatively reactive γ-sp2 or benzylic sp3 carbons 
was observed. As mentioned earlier, current methods for the direct fluorination of 
unactivated sp3 carbons suffer from poor site-selectivity, incompatibility with benzylic 
carbons, and low diastereoselectivity in many cases. Therefore, this reported process 






organic molecules. The detailed mechanistic study of this transformation is currently 
underway in our laboratory. 
 
3.4 Experimental 
Scheme 3.6 Starting Materials for Fluorination 
 General Methods. All solvents and commercially available reagents were 
purchased from commercial sources and used directly. Thin layer chromatography (TLC) 
was performed on EMD precoated plates (silica gel 60 F254, Art 5715) and visualized by 






Silica Gel 60 (200–300 Mesh) using a forced flow of 0.5–1.0 bar. 1H and 13C NMR spectra 
were obtained on a Bruker 500 MHz NMR Fourier transform spectrometer (500 MHz and 
125 MHz, respectively) or a Bruker AVANCE III–400 spectrometer (400 MHz and 100 
MHz, respectively) using tetramethylsilane as an internal reference, and chemical shifts (δ) 
and coupling constants (J) were expressed in ppm and Hz, respectively. Infrared spectra 
were obtained using a Thermo Nicolet IR 330 spectrometer or a Nicolet 6700 
spectrophotometer and reported as wave number (cm–1). Mass (MS) analysis was obtained 
using Agilent 1100 series LC/MSD system with Electrospray Ionization (ESI). Mass 
(HRMS) analysis was obtained using Agilent 6200 Accurate-Mass TOF LC/MS system 
with Electrospray Ionization (ESI). 
 Preparation of Starting Materials (Scheme 3.6): 
 Starting materials 3.1g22, 3.3a, 3.3d, and 3.3f23 were prepared according to 
literature procedures. 2-(Pyridin-2-yl)isopropylamine was prepared according to literature 
procedures.24 
 General procedure for protection of amino acids (3.1a-3.1e and 3.1h-3.1l): 
In a round-bottom flask fitted with Dean-Stark apparatus and a reflux condenser, phthalic 
acid anhydride (1.48 g, 10 mmol) and appropriate amino acids (10 mmol, or 20 mmol for 
lysine) were refluxed in toluene in the presence of 0.1 mL triethylamine overnight. The 
organic solvents were removed under reduced pressure to get a sticky oily mass. Water was 
added to this oily mass and the mixture was acidified with hydrochloric acid, and stirred 
for 30 min to get a white solid. This product was filtered off, washed with water, and dried 






 General procedure for synthesis of substrates 3.3g, h, i, j, and l: A solution of 
LDA (10 mmol) in THF was prepared from diisopropylamine (1.5 mL, 10.7 mmol) and 
2.5 M n-BuLi in hexane (4.0 mL, 10 mmol) at -78 C. To this LDA solution, the 
corresponding carboxylate ethyl ester (10 mmol) was added dropwise at -78 C, and the 
mixture was stirred at this temperature for 1 h. Alkyl halide (15 mmol) was then added 
dropwise to the solution at -78 C. After the addition, the mixture was warmed to room 
temperature and stirred overnight. Then the mixture was quenched with water at 0 C, 
and extracted with Et2O (15 mL x 3). The combined organic layer was washed with 
brine, dried over MgSO4, and evaporated in vacuo to give the crude esters.26 
 To the ester was added a solution of NaOH (2 M, 8.0 mL) and methanol (10 mL). 
The mixture was stirred overnight at 60 C. After removal of methanol in vacuo, the pH of 
the mixture was adjusted to 2 with 3.0 M HCl. The mixture was then saturated with NaCl 
and extracted with Et2O (15 mL x 3). The combined organic layer was washed with brine, 
dried over MgSO4, and evaporated in vacuo to give the crude carboxylic acid, which was 
used directly for the coupling with 2-(pyridin-2-yl)isopropylamine without further 
purification.26 
 General Procedure for amide synthesis: 
Acyl chlorides were prepared by following a reported procedure.27 Carboxylic acid (12 
mmol), thionyl chloride (4.4 mL, 60 mmol) and 3 drops of DMF were reacted in toluene 
(20 mL) at 80 °C in a 100 ml round-bottom flask equipped with a condenser and a stir bar 
for 4-5 h. After the reaction, toluene and the excess of thionyl chloride were removed by 
vacuum distillation. The crude residual acyl chloride was dissolved in anhydrous CH2Cl2 






 2-(Pyridin-2-yl)isopropylamine (10 mmol) and  2,6-lutidine  were  dissolved  in  
anhydrous CH2Cl2 (25 mL) in a 100 ml round-bottom flask followed by dropwise addition 
of acyl chloride solution in CH2Cl2 through cannula. The reaction mixture was stirred 
overnight. The reaction was diluted with CH2Cl2 (25 mL), washed by aqueous  1.0 M HCl  
(20  mL),  saturated NaHCO3 aqueous solution (20  mL),  brine  (30  mL),  and  dried  over 
Na2SO4. The organic solvent was removed by evaporation. Purification by column 
chromatography afforded pure amides. 
 2-(1,3-Dioxoisoindolin-2-yl)-N-(2-(pyridin-2-yl)propan-2-yl)butanamide 
(3.1a). White solid, overall yield from 2-aminobutyric acid: 2.10 g, 72%. 1H NMR (500 
MHz, CDCl3) δ 8.61 (br s, 1H), 8.25 (d, J = 4.5 Hz, 1H), 7.90-7.86 (m, 2H), 7.77-7.73 (m, 
2H), 7.72-7.67 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.16-7.11 (m, 1H), 4.81 (dd, J = 11.0, 
5.5 Hz, 1H), 2.48-2.28 (m, 2H), 1.76 (s, 3H), 1.75 (s, 3H), 0.99 (t, J = 7.5 Hz, 3H). 13C 
NMR (125 MHz, CDCl3) δ168.17, 167.37, 164.13, 147.25, 137.22, 134.12, 131.85, 123.37, 
121.86, 119.39, 56.60, 56.55, 27.36, 27.24, 22.00, 11.21. IR (neat) ῡ (cm-1) 3326, 3058, 
2975, 2934, 1774, 1715, 1593, 1514, 1470, 1432, 1384, 1093, 897, 787, 720. HRMS (ESI, 
m/z): calcd. for C20H22N3O3 (M+H)+: 352.1661, found: 352.1655. 
 2-(1,3-Dioxoisoindolin-2-yl)-N-(2-(pyridin-2-yl)propan-2-yl)pentanamide 
(3.1b). White solid, overall yield from norvaline: 2.16 g, 71%. 1H NMR (500 MHz, CDCl3) 
δ 8.55 (br s, 1H), 8.23 (dd, J = 5.0, 1.0 Hz, 1H), 7.90-7.85 (m, 2H), 7.76-7.65 (m, 3H), 
7.37 (d, J = 8.0 Hz, 1H), 7.15-7.09 (m, 1H), 4.88 (dd, J = 11.5, 5.0 Hz, 1H), 2.48-2.38 (m, 
1H), 2.22-2.14 (m, 1H), 1.74 (s, 3H), 1.74 (s, 3H), 1.43-1.32 (m, 2H), 0.98 (t, J = 7.5 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ 168.21, 167.55, 164.21, 147.27, 137.22, 134.05, 






ῡ (cm-1) 3327, 2964, 2933, 3873, 1774, 1714, 1678, 1513, 1469, 1383, 787, 720. HRMS 
(ESI, m/z): calcd. for C21H24N3O3 (M+H)+: 366.1818, found: 366.1825. 
 2-(1,3-Dioxoisoindolin-2-yl)-N-(2-(pyridin-2-yl)propan-2-yl)octanamide (3.1c). 
White solid, overall yield from 2-aminooctanoic acid: 2.32 g, 68%. 1H NMR (500 MHz, 
CDCl3) δ 8.57 (br s, 1H), 8.24-8.21 (m, 1H), 7.91-7.85 (m, 2H), 7.77-7.73 (m, 2H), 7.71-
7.67 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.14-7.10 (m, 1H), 5.72-5.56 (m, 1H), 4.87 (dd, J 
= 11.0, 5.0 Hz, 1H), 2.47-2.38 (m, 1H), 2.28-2.20 (m, 1H), 1.75 (s, 3H), 1.74 (s, 3H), 1.44-
1.20 (m, 7H), 0.85 (t, J = 7.0 Hz, 3H).  13C NMR (125 MHz, CDCl3) δ 168.18, 167.55, 
164.21, 147.26, 137.21, 134.07, 131.94, 123.42, 121.84, 119.41, 56.57, 55.11, 31.58, 28.69, 
28.63, 27.37, 27.25, 26.66, 22.52, 14.01. IR (neat) ῡ (cm-1) 3328, 3057, 2956, 2928, 2857, 
1775, 1715, 1681, 1514, 1432, 1382, 1085, 997, 787, 720. HRMS (ESI, m/z): calcd. for 
C24H30N3O3 (M+H)+: 408.2287, found: 408.2273. 
 2-(1,3-Dioxoisoindolin-2-yl)-4-phenyl-N-(2-(pyridin-2-yl)propan-2-
yl)butanamide (3.1d). White solid, overall yield from homophenylalanine: 2.50 g, 70%. 
1H NMR (500 MHz, CDCl3) δ 8.58 (br s, 1H), 8.17-8.14 (m, 1H), 7.85-7.81 (m, 2H), 7.73-
7.68 (m, 2H), 7.67-7.62 (m, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.20-7.16 (m, 4H), 7.10-7.04 
(m, 2H), 4.91 (dd, J = 11.0, 4.5 Hz, 1H), 2.87-2.57 (m, 4H), 1.72 (s, 6H). 13C NMR (125 
MHz, CDCl3) δ 168.05, 167.19, 164.00, 147.16, 140.44, 137.20, 134.04, 131.80, 128.37, 
128.31, 125.93, 123.31, 121.81, 119.33, 56.51, 54.81, 33.07, 29.92, 27.29, 27.20. IR (neat) 
ῡ (cm-1) 3324, 3060, 2979, 2931, 1775, 1715, 1594, 1514, 1470, 1452, 1432, 1381, 1266, 








(3.1e). White solid, overall yield from lysine: 2.84 g, 65%. 1H NMR (500 MHz, CDCl3) δ  
8.55 (br s, 1H), 8.23-8.20 (m, 1H), 7.87-7.83 (m, 2H), 7.80-7.65 (m, 7H), 7.36 (d, J = 8.5 
Hz, 1H), 7.14-7.09 (m, 1H), 4.84 (dd, J = 11.0, 5.0 Hz, 1H), 3.67 (t, J = 7.5 Hz, 2H), 2.50-
2.40 (m, 1H), 2.35-2.26 (m, 1H), 1.86-1.66 (m, 8H), 1.47-1.35 (m, 2H). 13C NMR (125 
MHz, CDCl3) δ 168.30, 168.12, 167.16, 164.12, 147.27, 137.19, 134.06, 133.84, 132.09, 
131.90, 123.46, 123.16, 121.84, 119.38, 56.57, 54.75, 37.61, 28.21, 28.02, 27.35, 27.22, 
24.05. IR (neat) ῡ (cm-1) 3327, 3058, 2977, 2937, 1773, 1713, 1570, 1468, 1382, 1036, 890, 
788, 720. HRMS (ESI, m/z): calcd. for C30H29N4O5 (M+H)+: 525.2138, found: 525.2145. 
 Benzyl 2-((2-(pyridin-2-yl)propan-2-yl)carbamoyl)piperidine-1-carboxylate 
(3.1f). Colorless oil, yield from Cbz-2-piperidinecarboxylic acid: 2.42 g, 76%. 1H NMR 
(500 MHz, CDCl3) δ 8.47-8.28 (m, 2H), 7.71-7.64 (m, 1H), 7.45-7.10 (m, 7H), 5.34-5.05 
(m, 2H), 4.94-4.76 (m, 1H), 4.31-4.11 (m, 1H), 3.13-2.96 (m, 1H), 2.40-2.32 (m, 1H), 1.77-
1.35 (m, 11H). 13C NMR (125 MHz, CDCl3) δ 169.43, 164.43, 156.36, 155.66, 147.65, 
137.02, 136.73, 128.44, 127.94, 127.70, 121.77, 119.27, 67.35, 56.39, 56.04, 55.49, 42.19, 
41.96, 27.51, 27.29, 26.12, 25.85, 25.07, 20.48. IR (neat) ῡ (cm-1) 3332, 3061, 2939, 2861, 
1699, 1592, 1506, 1472, 1418, 1357, 1257, 1199, 1044, 829, 843, 766, 735, 698. HRMS 
(ESI, m/z): calcd. for C22H28N3O3 (M+H)+: 382.2123, found: 382.2128. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-(4-fluorophenyl)-N-(2-(pyridin-2-yl)propan-2-
yl)propanamide (3.1h). White solid, overall yield from 4-fluoro-phenylalanine: 2.37 g, 
66%. 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 8.10 (d, J = 4.4 Hz, 1H), 7.83-7.81(m, 
2H), 7.73-7.67 (m, 3H), 7.37 (d, J = 8.0 Hz, 1H), 7.20-7.17 (m, 2H), 7.13-7.08 (m, 1H), 






NMR (100 MHz, CDCl3) δ 167.88, 166.65, 163.88, 161.66 (d, J = 243.0 Hz), 146.99, 
137.45, 134.12, 133.04 (d, J = 3.0 Hz), 131.59, 130.42 (d, J = 8.0 Hz), 123.44, 121.94, 
119.48, 115.40 (d, J = 22.0 Hz), 56.56, 55.99, 33.79, 27.30, 27.22. 19F NMR (376 MHz, 
CDCl3) -111.02 (d, J = 4.9 Hz), -162.8. IR (KBr) ῡ (cm-1) 3320, 3059, 2980, 2934, 1776, 
1716, 1680, 1510, 1471, 1382, 1223, 1108, 788, 721. HRMS (ESI, m/z): calcd. for 
C25H22FN3NaO3 (M+Na)+: 454.1543, found: 454.1537. 
 3-(4-Chlorophenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-(2-(pyridin-2-yl)propan-2-
yl)propanamide (3.1i). White solid23, overall yield from 4-chloro-phenylalanine: 2.50 g, 
67%. 1H NMR (500 MHz, CDCl3) δ 8.61 (br s, 1H), 8.09-8.05 (m, 1H), 7.82-7.78 (m, 2H), 
7.73-7.65 (m, 3H), 7.35 (d, J = 10.0 Hz, 1H), 7.18-7.13 (m, 4H), 7.11-7.07 (m, 1H), 5.15 
(dd, J = 10.5, 6.5 Hz, 1H), 3.68-3.58 (m, 2H), 1.75 (s, 3H), 1.74 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 167.88, 166.50, 163.95, 147.11, 137.28, 135.93, 134.13, 132.53, 131.62, 
130.29, 128.72, 123.48, 121.89, 119.38, 56.6, 55.81, 33.97, 27.26, 27.24. IR (neat) ῡ (cm-
1) 3317, 2978, 2930, 1776, 1714, 1679, 1512, 1492, 1469, 1381, 1092, 1015, 961, 875, 786, 
720. Ms (ESI): m/z = 448.1 [M+H]+. 
 3-(4-Bromophenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-(2-(pyridin-2-yl)propan-2-
yl)propanamide  (3.1j). White solid, overall yield from 4-bromo-phenylalanine: 2.80 g, 
68%. 1H NMR (400 MHz, CDCl3) δ 8.60 (s, 1H), 8.16 (d, J = 3.2 Hz, 1H), 7.84-7.72 (m, 
5H), 7.43 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.21-7.18 (m, 1H), 7.12 (d, J = 8.4 
Hz, 2H), 5.17 (dd, J = 10.0, 6.8 Hz, 1H), 3.71-3.60 (m, 2H), 1.76 (s, 6H). 13C NMR (100 
MHz, CDCl3) δ 167.87, 166.63, 163.70, 146.70, 137.86, 136.40, 134.14, 131.65, 131.59, 
130.68, 123.49, 122.08, 120.64, 119.68, 56.49, 55.66, 34.02, 27.31, 27.19. 19F NMR (376 






1382, 1112, 1012, 876, 786, 721, 530. HRMS (ESI, m/z): calcd. for C25H22BrN3NaO3 
(M+Na)+: 514.0742, found: 514.0717. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-(4-nitrophenyl)-N-(2-(pyridin-2-yl)propan-2-
yl)propanamide (3.1k). Pink solid, overall yield from 4-nitro-phenylalanine: 2.22 g, 58%. 
1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.10-8.07 (m, 3H), 7.84-7.70 (m, 5H), 7.46-
7.42 (m, 3H), 7.22-7.19 (m, 1H), 5.25 (dd, J = 11.2, 6.0 Hz, 1H), 3.87-3.75 (m, 2H), 1.80 
(s, 6H). 13C NMR (100 MHz, CDCl3) δ 167.73, 166.08, 163.61, 146.83, 146.78, 145.51, 
137.71, 134.38, 131.38, 129.86, 123.75, 123.58, 122.08, 119.56, 56.51, 55.23, 34.41, 27.21, 
27.19. 19F NMR (376 MHz, CDCl3) 168.7. IR (KBr) ῡ (cm-1) 3317, 3059, 2981, 2934, 1776, 
1715, 1597, 1519, 1346, 1111, 1087, 886, 787, 721, 557. HRMS (ESI, m/z): calcd. for 
C25H22N4NaO5 (M+Na)+: 481.1488, found: 481.1461. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-(naphthalen-2-yl)-N-(2-(pyridin-2-yl)propan-2-
yl)propanamide (3.1l). White solid, overall yield from 2-naphthylalanine: 2.12 g, 55%. 
1H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 8.02 (d, J = 2.8 Hz, 1H), 7.82-7.63 (m, 9H), 
7.45-7.35 (m, 4H), 7.09-7.04 (m, 1H), 5.38 (dd, J = 9.2, 7.2 Hz, 1H), 3.90-3.84 (m, 2H), 
1.79 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 168.02, 166.89, 163.83, 146.98, 137.45, 
134.92, 134.03, 133.48, 132.34, 131.65, 128.36, 127.77, 127.60, 127.57, 126.97, 125.96, 
125.54, 123.38, 121.93, 119.46, 56.65, 55.91, 34.92, 27.36, 27.31. 19F NMR (376 MHz, 
CDCl3) 162.6. IR (KBr) ῡ (cm-1) 3320, 3055, 2979, 2932, 1775, 1715, 1676, 1510, 1382, 
1099, 874, 788, 720, 479. HRMS (ESI, m/z): calcd. for C29H25N3NaO3 (M+Na)+: 486.1794, 
found: 486.1784. 
 N-(2-(Pyridin-2-yl)propan-2-yl)butyramide (3.3a). Colorless oil2, yield from 






2H), 7.41 (d, J = 8.0 Hz, 1H), 7.21-7.17 (m, 1H), 2.24 (t, J = 7.5 Hz, 2 H), 1.76 (s, 6H), 
1.74-1.65 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 172.24, 164.73, 
147.60, 137.04, 121.80, 119.50, 56.36, 39.77, 27.56, 19.21, 13.74. IR (neat) ῡ (cm-1) 3312, 
3062, 2964, 2932, 2872, 1650, 1591, 1569, 1542, 1475, 1430, 1379, 1291, 1214, 1127, 993, 
787, 748, 623. Ms (ESI): m/z = 207.2 [M+H]+. 
 N-(2-(Pyridin-2-yl)propan-2-yl)tetradecanamide (3.3b). White solid, yield from 
myristic acid: 2.84 g, 82%. 1H NMR (500 MHz, CDCl3) δ 8.52-8.49 (m, 1H), 7.73-7.68 
(m, 2H), 7.42-7.38 (m, 1H), 7.20-7.16 (m, 1H), 2.25 (t, J = 7.5 Hz, 2H), 1.76 (s, 6H), 1.70-
1.62 (m, 2H), 1.36-1.20 (m, 19H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) 
δ 172.40, 164.76, 147.60, 137.01, 121.77, 119.49, 56.35, 37.86, 31.93, 29.69, 29.66, 29.64, 
29.53, 29.36, 27.56, 25.81, 22.69. IR (neat) ῡ (cm-1) 3317, 3066, 2954, 2919, 2872, 2850, 
1646, 1547, 1473, 1464, 1355, 784, 747, 647, 621. HRMS (ESI, m/z): calcd. for C22H39N2O 
(M+H)+: 347.3062, found: 347.3065. 
 3-Cyclopentyl-N-(2-(pyridin-2-yl)propan-2-yl)propanamide (3.3c). White solid, 
yield from cyclopentanepropionic acid: 2.23 g, 86%. 1H NMR (500 MHz, CDCl3) δ 8.53-
8.50 (m, 1H), 7.73-7.65 (m, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.21-7.16 (m, 1H), 2.30-2.24 
(m, 2H), 1.84-1.45 (m, 15H), 1.18-1.07 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 172.51, 
164.75, 147.62, 137.03, 121.79, 119.50, 56.34, 39.82, 37.15, 32.52, 31.99, 27.55, 25.18. 
IR (neat) ῡ (cm-1) 3310, 3062, 2948, 2865, 1651, 1591, 1542, 1474, 1430, 1380, 1328, 
1292, 1207, 1126, 993, 786, 747, 623. HRMS (ESI, m/z): calcd. for C16H25N2O (M+H)+: 
261.1967, found: 261.1956. 
 5-Phenyl-N-(2-(pyridin-2-yl)propan-2-yl)pentanamide (3.3e). White solid, 






1H), 7.73-7.66 (m, 2H), 7.38 (d, J = 8.0 Hz, 1H), 7.27-7.23 (m, 2H), 7.18-7.13 (m, 4H), 
2.64 (t, J = 7.0 Hz, 2H), 2.28 (t, J = 7.5 Hz, 2H), 1.77-1.63 (m, 10H). 13C NMR (125 MHz, 
CDCl3) δ 172.06, 164.64, 147.58, 142.41, 137.03, 128.40, 128.26, 125.66, 121.79, 119.47, 
56.36, 37.56, 35.76, 31.07, 27.54, 25.44. IR (neat) ῡ (cm-1) 3317, 3004, 2919, 2850, 1647, 
1547, 1464, 1428, 1175, 784, 747, 647. HRMS (ESI, m/z): calcd. for C19H25N2O (M+H)+: 
297.1967, found: 297.1964. 
 2-Isopropyl-N-(2-(pyridin-2-yl)propan-2-yl)pentanamide (3.3g). White solid, 
overall yield from ethyl isovalerate and n-iodopropane: 1.05 g, 48%. 1H NMR (500 MHz, 
CDCl3) δ 8.53-8.47 (m, 1H), 7.82 (br s, 1H), 7.73-7.68 (m, 1H), 7.41 (d, J = 8.0 Hz, 1H), 
7.20-7.16 (m, 1H), 1.85-1.72 (m, 8H), 1.65-1.55 (m, 1H), 1.50-1.20 (m, 3H), 1.00-0.87 (m, 
8H). 13C NMR (125 MHz, CDCl3) δ 174.51, 164.84, 147.55, 136.96, 121.74, 119.54, 56.43, 
55.72, 32.70, 30.98, 27.50, 27.47, 21.07, 21.02, 20.57, 14.32. IR (neat) ῡ (cm-1) 3308, 3052, 
2955, 2933, 2870, 1644, 1593, 1541, 1476, 1428, 1380, 1271, 1234, 1125, 788, 750, 738, 
666, 624. HRMS (ESI, m/z): calcd. for C16H27N2O (M+H)+: 263.2123, found: 261.2119. 
 2-Benzyl-3-methyl-N-(2-(pyridin-2-yl)propan-2-yl)butanamide (3.3h). White 
solid, overall yield from ethyl isovalerate and benzyl bromide: 1.09 g, 42%. 1H NMR (500 
MHz, CDCl3) δ 8.43-8.40 (m, 1H), 7.62-7.56 (m, 1H), 7.29 (br s, 1H), 7.23-7.18 (m, 4H), 
7.17-7.14 (m, 1H), 7.13-7.08 (m, 2H), 2.89-2.84 (m, 2H), 2.14-2.08 (m, 1H), 1.98-1.90 (m, 
1H), 1.62 (s, 3H), 1.49 (s, 3H), 1.07 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H). 13C NMR 
(125 MHz, CDCl3) δ 173.03, 164.60, 147.45, 140.66, 136.75, 129.19, 128.12, 125.82, 
121.52, 119.37, 57.84, 56.43, 36.62, 30.95, 27.42, 27.34, 20.76. IR (neat) ῡ (cm-1) 3335, 
2967, 2931, 2871, 1651, 1593, 1569, 1509, 1473, 1430, 1379, 1227, 1126, 786, 746, 700, 






 2-Cyclohexyl-N-(2-(pyridin-2-yl)propan-2-yl)pentanamide (3.3i). White solid, 
overall yield from ethyl 2-cyclohexylacetate and n-iodopropane: 1.39 g, 55%. 1H NMR 
(500 MHz, CDCl3) δ 8.51 (d, J = 4.5 Hz, 1H), 7.79 (br s, 1H), 7.73-7.68 (m, 1H), 7.40 (d, 
J = 8.0 Hz, 1H), 7.20-7.16 (m, 1H), 1.89-1.83 (m, 2H), 1.78-1.30 (m, 14H), 1.27-0.86 (m, 
9H). 13C NMR (125 MHz, CDCl3) δ 174.51, 164.84, 147.54, 136.96, 121.73, 119.55, 56.44, 
54.80, 40.36, 32.23, 31.29, 30.95, 27.55, 27.49, 26.60, 26.47, 26.37, 21.02, 14.33. IR (neat) 
ῡ (cm-1) 3303, 3007, 2928, 2851, 1644, 1542, 1477, 1429, 1358, 1252, 1224, 787, 749. 
HRMS (ESI, m/z): calcd. for C19H31N2O (M+H)+: 303.2436, found: 303.2435. 
 2-Cyclohexyl-3-phenyl-N-(2-(pyridin-2-yl)propan-2-yl)propanamide (3.3j). 
White solid, overall yield from ethyl 2-cyclohexylacetate and benzyl bromide: 1.52 g, 52%. 
1H NMR (500 MHz, CDCl3) δ 8.43-8.40 (m, 1H), 7.61-7.56 (m, 1H), 7.28 (br s, 1H), 7.22-
7.07 (m, 7H), 2.92-2.81 (m, 2H), 2.17-2.10 (m, 1H), 1.99-1.93 (m, 1H), 1.83-1.57 (m, 8H), 
1.47 (s, 3H), 1.32-1.02 (m, 5H). 13C NMR (125 MHz, CDCl3) δ 173.01, 164.62, 147.47, 
140.75, 136.75, 129.23, 128.10, 125.78, 121.52, 119.37, 57.06, 56.43, 40.39, 36.22, 31.13, 
31.09, 27.48, 27.24, 26.56, 26.47, 26.35. IR (neat) ῡ (cm-1) 3317, 2925, 2851, 1649, 1592, 
1535, 1497, 1473, 1449, 1430, 1379, 1248, 1211, 1125, 784, 745, 700, 673. HRMS (ESI, 
m/z): calcd. for C23H31N2O (M+H)+: 351.2436, found: 351.2433. 
 2-Phenyl-N-(2-(pyridin-2-yl)propan-2-yl)butanamide (3.3k). White solid, yield 
from 2-phenylbutyric acid: 2.12 g, 75%. 1H NMR (500 MHz, CDCl3) δ 8.46-8.43 (m, 1H), 
7.74 (br s, 1H), 7.68-7.63 (m, 1H), 7.38-7.29 (m, 5H), 7.26-7.21 (m, 1H), 7.16-7.12 (m, 
1H), 3.32 (t, J = 7.5 Hz, 1H), 2.22-2.13 (m, 1H), 1.85-1.74 (m, 1H), 1.72 (s, 3H), 1.66 (s, 
3H), 0.92 (t, J = 7.5Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 172.53, 164.61, 147.55, 140.71, 






IR (neat) ῡ (cm-1) 3327, 2966, 2932, 2874, 1655, 1592, 1570, 1505, 1473, 1452, 1431, 
1275, 1222, 1127, 786, 747, 731, 699. HRMS (ESI, m/z): calcd. for C18H23N2O (M+H)+: 
283.1810, found: 283.1807. 
 2-(Naphthalen-1-yl)-N-(2-(pyridin-2-yl)propan-2-yl)butanamide (3.3l). White 
solid, overall yield from ethyl 2-naphthylacetate and iodoethane: 2.16 g, 65%. 1H NMR 
(400 MHz, CDCl3) δ 8.42 (d, J = 4.4 Hz, 1H), 7.87-7.83 (m, 5H), 7.71-7.66 (m, 1H), 7.56 
(d, J = 9.2 Hz, 1H), 7.51-7.46 (m, 2H), 7.35 (d, J = 8.4 Hz, 1H), 7.17 (dd, J = 6.8, 5.2 Hz, 
1H), 3.54 (t, J = 7.6 Hz, 1H), 2.32-2.25  (m, 1H), 1.98-1.87 (m, 1H), 1.76 (s, 3H), 1.69 (s, 
3H), 0.97 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 172.57, 164.37, 147.15, 
138.19, 137.45, 133.57, 132.58, 128.25, 127.83, 127.62, 126.77, 126.19, 125.97, 125.56, 
121.88, 119.62, 56.40, 56.06, 27.46, 26.62, 12.46. 19F NMR (376 MHz, CDCl3) 171.0. IR 
(KBr) ῡ (cm-1) 3326, 3054, 2966, 2932, 2873, 1656, 1506, 1473, 1380, 1127, 815, 748, 
478. HRMS (ESI, m/z): calcd. for C22H25N2O (M+H)+: 333.1967, found: 333.1969. 
 General procedure for Palladium-Catalyzed β-Fluorination of Amides: 
An oven-dried 50 mL Schlenk flask was charged with Pd(OAc)2 (6.7 mg, 0.03 mmol), 
Selectfluor (265.7 mg, 0.75 mmol), Ag2CO3 (165.4 mg, 0.6 mmol) and Fe(OAc)2, and then 
a solution of amide (3.1 or 3.3, 0.30 mmol) in DCE (3.0 mL) was added, followed by 
addition of iPrCN or MeCN. The vial was sealed, and the reaction mixture was stirred 
vigorously at 150 ˚C for 14 h. The mixture was cooled to room temperature, diluted with 
EtOAc (10 mL), filtered through a celite pad, and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (gradient eluent of 5~20% acetone in 







yl)butanamide (3.2a + 3.2a’), 84.2 mg, 76% yield (d.r. = 7:1), with 0.3 equivalents of 
Fe(OAc)2 and 300 µL of iPrCN. Compound 3.2a: white solid; 1H NMR (500 MHz, CDCl3) 
δ 8.62 (d, J = 7.5 Hz, 1H), 8.49-8.46 (m, 1H), 7.89-7.84 (m, 2H), 7.75-7.66 (m, 3H), 7.38 
(d, J = 8.0 Hz, 1H), 7.18-7.14 (m, 1H), 5.86-5.70 (m, 1H), 4.91 (dd, J = 14.5, 9.0 Hz, 1H), 
1.77 (s, 3H), 1.74 (s, 3H), 1.44 (dd, J = 25.0, 6.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 
167.94, 164.88, 164.08, 147.75, 137.06, 134.26, 131.90, 123.72, 121.86, 119.28, 88.68 (d, 
J = 164.8 Hz), 57.68 (d, J = 30.5 Hz), 57.38, 27.51, 27.42, 19.08 (d, J = 22.0 Hz). 19F 
NMR (470 MHz, CDCl3) δ -171.9 (m, 1F). IR (neat) ῡ (cm-1) 3364, 3324, 2984, 2936, 2912, 
1773, 1716, 1684, 1520, 1471, 1455, 1389, 1335, 1297, 1116, 1090, 913, 887, 789, 717, 
652. HRMS (ESI, m/z): calcd. for C20H21FN3O3 (M+H)+: 370.1567, found: 370.1568. 
Compound 3.2a’: white solid; 1H NMR (500 MHz, CDCl3) δ 8.60 (br s, 1H), 8.24-8.21 (m, 
1H), 7.94-7.89 (m, 2H), 7.79-7.74 (m, 2H), 7.70-7.65 (m, 1H), 7.35 (d, J = 8.0 Hz, 1H), 
7.13-7.09 (m, 1H), 5.62-5.55(m, 1H), 4.87 (dd, J = 10.0, 9.0 Hz, 1H), 1.73 (s, 6H), 1.63 
(dd, J = 10.0, 6.5, 3H). 13C NMR (125 MHz, CDCl3) δ 167.78, 164.65, 163.87, 147.47, 
137.15, 134.27, 131.83, 123.68, 121.89, 119.32, 86.31 (d, J = 172.9 Hz), 59.33 (d, J = 20.0 
Hz), 56.88, 27.26 (d, J =28.9 Hz), 19.67 (d, J = 21.3 Hz). IR (neat) ῡ (cm-1) 3313, 2956, 
2924, 2853, 1772, 1718, 1684, 1521, 1472, 1457, 1385, 1297, 1125, 1067, 913, 886, 788, 
719, 668. 19F NMR (470 MHz, CDCl3) δ -191.7 (m, 1F). HRMS (ESI, m/z): calcd. for 
C20H21FN3O3 (M+H)+: 370.1567, found: 370.1570. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-N-(2-(pyridin-2-yl)propan-2-
yl)pentanamide (3.2b + 3.2b’). 84.0 mg, 73% yield (d.r. = 8:1), with 0.3 equivalents of 






δ 8.59 (d, J = 6.5 Hz, 1H), 8.50 (br s, 1H), 7.90-7.83 (m, 2H), 7.76-7.66 (m, 3H), 7.42-7.36 
(m, 1H), 7.20-7.14 (m, 1H), 5.70-5.53 (m, 1H), 5.00-4.92 (m, 1H), 1.87-1.56 (m, 8H), 1.05 
(t, J = 6.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 167.99, 165.09, 164.11, 147.81, 137.05, 
134.24, 131.94, 123.70, 121.85, 119.28, 92.37 (d, J = 165.3 Hz), 57.42, 56.09 (d, J = 30.9 
Hz), 27.52, 27.46, 25.79 (d, J = 20.8), 8.26 (d, J = 4.3 Hz). IR (neat) ῡ (cm-1) 3323, 2976, 
2928, 1779, 1718, 1681, 1513, 1470, 1384, 1362, 1100, 1077, 671. 19F NMR (470 MHz, 
CDCl3) δ -183.6 (m, 1F). HRMS (ESI, m/z): calcd. for C21H23FN3O3 (M+H)+: 384.1723, 
found: 384.1725. Compound 3.2b’: white solid; 1H NMR (500 MHz, CDCl3) δ 8.58 (br s, 
1H), 8.23-8.20 (m, 1H), 7.93-7.88 (m, 2H), 7.79-7.64 (m, 2H), 7.70-7.66 (m, 1H), 7.35 (d, 
J = 8.5 Hz, 1H) 7.13-7.09 (m, 1H), 5.48-5.33 (m, 1H), 5.00-4.92 (dd, J = 10.5, 8.5 Hz, 
1H), 2.13-1.97 (m, 1H), 1.88-1.68 (m, 7H), 1.11 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ 167.82, 164.88, 164.82, 163.86, 147.45, 137.15, 134.26, 131.81, 123.67, 121.88, 
119.32, 90.52 (d, J = 175.6 Hz), 57.57 (d, J = 19.6 Hz), 56.87, 27.27 (d, J = 28.3 Hz), 
26.67 (d, J = 20.3 Hz), 9.23 (d, J = 4.1 Hz). IR (neat) ῡ (cm-1) 3317, 3060, 2975, 2926, 
2852, 1773, 1721, 1685, 1512, 1471, 1380, 1294, 1194, 1075, 788, 719. 19F NMR (470 
MHz, CDCl3) δ -190.7 (m, 1F). HRMS (ESI, m/z): calcd. for C21H23FN3O3 (M+H)+: 
384.1723, found: 384.1728. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-N-(2-(pyridin-2-yl)propan-2-
yl)octanamide 3.2c + 3.2c’). 89.4 mg, 70% yield (d.r. = 9:1), with 0.3 equivalents of 
Fe(OAc)2 and 300 µL of iPrCN. Compound 3.2c: White solid; 1H NMR (500 MHz, CDCl3) 
δ 8.56 (d, J = 7.5 Hz, 1H), 8.49 (d, J = 3.5 Hz, 1H), 7.89-7.84 (m, 2H), 7.75-7.65 (m, 3H), 
7.38 (d, J = 8.0 Hz, 1H), 7.17-7.14 (m, 1H), 5.74-5.55 (m, 1H), 4.94 (dd, J = 13.0, 10.0, 






CDCl3) δ 167.98, 165.08, 164.19, 147.84, 137.02, 134.21, 132.00, 123.72, 121.83, 119.27, 
91.61 (d, J = 166.9 Hz), 57.46, 56.51 (d, J = 30.8 Hz), 32.68 (d, J = 20.5 Hz), 31.41, 27.55, 
27.48, 23.78 (d, J = 2.9 Hz), 22.45, 13.89. IR (neat) ῡ (cm-1) 3328, 3058, 2956, 2928, 1775, 
1715, 1682, 1594, 1514, 1379, 1360, 1335, 1267, 1201, 1193, 1125, 1085, 997, 877, 787, 
719, 650. 19F NMR (470 MHz, CDCl3) δ -181.6 (m, 1F). HRMS (ESI, m/z): calcd. for 
C24H29FN3O3 (M+H)+: 426.2193, found: 426.2190. Compound 3.2c’: white solid; 1H NMR 
(500 MHz, CDCl3) δ 8.57 (br s, 1H), 8.24-8.20 (m, 1H), 7.93-7.87 (m, 2H), 7.79-7.73 (m, 
2H), 7.69-7.64 (m, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.13-7.09 (m, 1H), 5.53-5.38 (m, 1H), 
4.91 (dd, J = 10.5, 8.5, 1H), 2.07-1.90 (m, 1H), 1.81-1.45 (m, 9H), 1.38-1.24 (m, 4H), 
0.91-0.85 (m, 3H). 13C NMR (125 MHz, CDCl3) δ 167.83, 164.87, 163.89, 147.45, 137.13, 
134.25, 131.82, 123.70, 121.88, 119.32, 89.52 (d, J = 175.5 Hz), 57.94 (d, J = 19.9 Hz), 
56.88, 33.48 (d, J = 20.0 Hz), 31.51, 27.41, 27.15, 24.63 (d, J = 2.5 Hz), 22.52, 13.99. IR 
(neat) ῡ (cm-1) 3314, 2955, 2926, 2857, 1773, 1718, 1684, 1594, 1520, 1381, 1195, 1125, 
1086, 997, 875, 787, 719, 668. 19F NMR (470 MHz, CDCl3) δ -190.6 (m, 1F). HRMS (ESI, 
m/z): calcd. for C24H29FN3O3 (M+H)+: 426.2193, found: 426.2198. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-4-phenyl-N-(2-(pyridin-2-yl)propan-2-
yl)butanamide (3.2d). White solid, 101.6 mg, 76% yield, with 0.25 equivalents of 
Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (500 MHz, CDCl3) δ 8.51 (d, J = 7.5 Hz, 1H), 
8.47-8.43 (m, 1H), 7.88-7.84 (m, 2H), 7.76-7.71 (m, 2H), 7.70-7.65 (m, 1H), 7.36 (d, J = 
9.5 Hz, 1H), 7.27-7.13 (m, 6H), 5.96-5.80 (m, 1H), 4.98 (dd, J = 13.5, 9.5 Hz, 1H), 3.16-
2.90 (m, 2H), 1.74 (s, 3H), 1.72 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 167.94, 164.74, 
164.00, 147.80, 137.02, 135.61, 135.60, 134.24, 131.91, 129.51, 128.46, 126.87, 123.71, 






27.46, 27.45. IR (neat) ῡ (cm-1) 3325, 3061, 3030, 2980, 2923, 1779, 1717, 1682, 1513, 
1471, 1385, 1336, 1124, 1088, 996, 787, 750, 723, 702, 650. 19F NMR (470 MHz, CDCl3) 
δ -179.1 (m, 1F). HRMS (ESI, m/z): calcd. for C26H25FN3O3 (M+H)+: 446.1880, found: 
446.1890. 
 2,6-Bis(1,3-dioxoisoindolin-2-yl)-3-fluoro-N-(2-(pyridin-2-yl)propan-2-
yl)hexanamide (3.2e). White solid, 105.8 mg,: 65% yield, with 0.25 equivalents of 
Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (500 MHz, CDCl3) δ 8.60 (d, J = 7.5 Hz, 1 H), 
8.48-8.45 (m, 1H), 7.87-7.82 (m, 2H), 7.79-7.66 (m, 7H), 7.37 (d, J = 8.0 Hz, 1H), 7.18-
7.14 (m, 1H), 5.75-5.58 (m, 1H), 4.93 (dd, J = 14.0, 9.0 Hz, 1H), 3.68 (t, J = 8.0 Hz, 2H), 
2.02-1.64 (m, 10H), 1.60 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 168.21, 167.94, 164.74, 
164.04, 147.77, 137.05, 134.23, 133.88, 132.05, 131.92, 123.76, 123.21, 121.85, 119.25, 
91.01 (d, J = 168.3 Hz), 57.42, 56.38 (d, J = 30.6 Hz), 37.51, 30.08 (d, J = 20.5 Hz), 27.48, 
27.42, 23.49 (d, J = 2.9 Hz). IR (neat) ῡ (cm-1) 3321, 3059, 2977, 2933, 1774, 1683, 1613, 
1571, 1451, 1433, 1393, 1382, 1268, 1088, 1040, 996, 881, 788, 734, 720. 19F NMR (470 
MHz, CDCl3) δ -181.8 (m, 1F). HRMS (ESI, m/z): calcd. for C30H28FN4O5 (M+H)+: 
543.2044, found: 543.2044. 
 Benzyl 3-fluoro-2-((2-(pyridin-2-yl)propan-2-yl)carbamoyl)piperidine-1-
carboxylate (3.2f). Colorless oil, 98.3 mg,: 82% yield, with 0.3 equivalents of Fe(OAc)2 
and 300 µL of iPrCN. 1H NMR (500 MHz, CDCl3) δ 8.50-8.44 (m, 1H), 8.04 (br s, 1H), 
7.70-7.63 (m, 1H), 7.41-7.22 (m, 6H), 7.17-7.12 (m, 1H), 5.23-4.69 (m, 4H), 4.07-3.85 (m, 
1H), 3.36-3.23 (m, 1H), 2.08-1.93 (m, 1H), 1.85-1.66 (m, 7H), 1.65-1.50 (m, 1H). 13C 
NMR (125 MHz, CDCl3) δ 166.54, 164.27, 156.34, 147.80, 136.92, 136.42, 128.46, 128.02, 






22.59. IR (neat) ῡ (cm-1) 3335, 3062, 2953, 2870, 1683, 1592, 1570, 1514, 1430, 1357, 
1261, 1158, 1114, 1038, 996, 894, 787, 735, 698. 19F NMR (470 MHz, CDCl3) δ -179.0 
(m, 1F). HRMS (ESI, m/z): calcd. for C22H27FN3O3 (M+H)+: 400.2036, found: 400.2038. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-3-phenyl-N-(2-(pyridin-2-yl)propan-2-
yl)propanamide (3.2g). White solid, 110.0 mg, 85% yield, with no Fe(OAc)2 and 300 µL 
of iPrCN. 1H NMR (500 MHz, CDCl3) δ 8.84 (d, J = 7.5 Hz, 1H), 8.51-8.48 (m, 1H), 7.74-
7.68 (m, 3H), 7.63-7.58 (m, 2H), 7.45-7.40 (m, 3H), 7.30-7.23 (m, 3H), 7.20-7.16 (m, 1H), 
6.55 (dd, J = 47.5, 9.5 Hz, 1H), 5.34 (dd, J = 14.5, 9.5 Hz, 1H), 1.83 (s, 3H), 1.79 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 167.40, 164.63 (d, J = 1.9 Hz), 164.07, 147.77, 137.11, 
135.59 (d, J = 18.9 Hz), 134.00, 131.57, 129.66, 128.60, 127.19 (d, J = 10.9 Hz), 123.48, 
121.91, 119.31, 92.00 (d, J = 168.9 Hz), 57.49, 56.78 (d, J = 35.5 Hz), 27.53, 27.45. IR 
(neat) ῡ (cm-1) 3316, 3062, 2977, 2924, 2853, 1778, 1718, 1682, 1594, 1514, 1471, 1389, 
1296, 1264, 1194, 1122, 1088, 997, 957, 787, 749, 722, 700. 19F NMR (470 MHz, CDCl3) 
δ -164.1 (m, 1F). HRMS (ESI, m/z): calcd. for C25H23FN3O3 (M+H)+: 432.1723, found: 
432.1725. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-3-(4-fluorophenyl)-N-(2-(pyridin-2-
yl)propan-2-yl)propanamide (3.2h). Colorless oil, 87.6 mg, 65% yield, with 0.3 
equivalents of Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (400 MHz, CDCl3) δ 8.84 (d, J = 
5.6 Hz, 1H), 8.53 (d, J = 4.0 Hz, 1H), 7.80-7.65 (m, 5H), 7.45- 742 (m, 3H), 7.26- 7.23 (m, 
1H), 6.98 (t, J = 8.4 Hz, 2H), 6.57 (dd, J = 47.6, 9.6 Hz, 1H), 5.33 (dd, J = 14.4, 9.6 Hz, 
1H), 1.85 (s, 3H), 1.81 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.36, 164.58 (d, J = 2.0 
Hz), 163.71, 163.26 (dd, J = 247.0, 3.0 Hz), 147.29, 137.77, 134.15, 131.54 (dd, J =19.0, 






Hz), 91.27 (d, J = 170.0 Hz), 57.32, 56.68 (d, J = 36.0 Hz), 27.49, 27.43. IR (KBr) ῡ (cm-
1) 3315, 3058, 2980, 2929, 1779, 1717, 1684, 1514, 1386, 1228, 1122, 998, 841, 721, 566, 
528. 19F NMR (376 MHz, CDCl3) δ -111.0, 162.8. HRMS (ESI, m/z): calcd. for 
C25H21F2N3NaO3 (M+H)+: 472.1449, found: 472.1436. 
 3-(4-Chlorophenyl)-2-(1,3-dioxoisoindolin-2-yl)-3-fluoro-N-(2-(pyridin-2-
yl)propan-2-yl)propanamide (3.2i). White solid, 100.6 mg, 72% yield, with 0.3 
equivalents of Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (500 MHz, CDCl3) δ 8.87 (d, J = 
6.5 Hz, 1H), 8.50-8.47 (m, 1H), 7.75-7.69 (m, 3H), 7.67-7.62 (m, 2H), 7.42-7.35 (m, 3H), 
7.28-7.24 (m, 2H), 7.21-7.17 (m, 1H), 6.54 (dd, J = 48.0, 9.5 Hz, 1H), 5.29 (dd, J = 15.0, 
9.5 Hz, 1H), 1.82 (s, 3H), 1.78 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 167.43, 164.33 (d, 
J = 2.3 Hz), 163.70, 147.71, 137.17, 135.59 (d, J = 3.4 Hz), 134.23 (d, J = 12.6 Hz), 134.12, 
131.50, 128.93, 128.61 (d, J = 5.4 Hz), 123.62, 121.97, 119.32, 91.27 (d, J = 169.6 Hz), 
57.47, 56.71 (d, J = 35.9 Hz), 27.48, 27.40. IR (neat) ῡ (cm-1) 3332, 3060, 2880, 2936, 
1781, 1722, 1679, 1596, 1469, 1392, 1124, 1090, 836, 786, 751, 718. 19F NMR (470 MHz, 
CDCl3) δ -164.3 (m, 1F). HRMS (ESI, m/z): calcd. for C25H22ClFN3O3 (M+H)+: 466.1334, 
found: 466.1336. 
 3-(4-Bromophenyl)-2-(1,3-dioxoisoindolin-2-yl)-3-fluoro-N-(2-(pyridin-2-
yl)propan-2-yl)propanamide (3.2j). White solid, 111.8 mg, 73% yield, with 0.3 
equivalents of Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 
6.4 Hz, 1H), 8.51 (d, J = 4.4 Hz, 1H), 7.76-7.66 (m, 5H), 7.43 (d, J = 8.4 Hz, 3H), 7.33 
(dd, J = 8.4, 1.2 Hz, 2H), 7.22 (dd, J = 7.2, 5.2 Hz, 1H), 6.55 (dd, J = 47.6, 9.6 Hz, 1H), 
5.31 (dd, J = 14.4, 9.6 Hz, 1H), 1.84 (s, 3H), 1.80 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 






131.88, 131.48, 128.88 (d, J = 5.0 Hz), 123.91 (d, J = 4.0 Hz), 123.64, 122.11, 119.53, 
91.28 (d, J = 169.0 Hz), 57.38, 56.63 (d, J = 35.0 Hz) 27.48, 27.42. IR (KBr) ῡ (cm-1) 
3314, 3059, 2981, 2929, 1779, 1720, 1685, 1514, 1385, 1013, 724. 19F NMR (376 MHz, 
CDCl3) δ -164.6. HRMS (ESI, m/z): calcd. for C25H21BrFN3NaO3 (M+Na)+: 532.0648, 
found: 532.0629. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-3-(4-nitrophenyl)-N-(2-(pyridin-2-
yl)propan-2-yl)propanamide (3.2k). White solid, 87.2 mg, 61% yield, with 0.3 
equivalents of Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 
5.6 Hz, 1H), 8.46 (d, J = 4.8 Hz, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.77-7.73 (m, 3H), 7.70-
7.63 (m, 4H), 7.43 (d, J = 8.0 Hz, 1H), 7.23-7.20 (m, 1H), 6.69 (dd, J = 47.6, 9.6 Hz, 1H), 
5.33 (dd, J = 15.2, 9.6 Hz, 1H), 1.84 (s, 3H), 1.80 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
167.39, 163.88 (d, J = 1.0 Hz), 163.63, 148.50 (d, J = 3.0 Hz), 147.33, 142.55 (d, J = 19.0 
Hz), 137.65, 134.43, 131.30, 128.11 (d, J = 6.0 Hz), 123.82, 123.76, 122.18, 119.55, 90.58 
(d, J = 172.0 Hz), 57.36, 56.73 (d, J = 34.0 Hz), 27.40, 27.35. IR (KBr) ῡ (cm-1) 3318, 
3061, 2981, 2922, 1779, 1718, 1683, 1526, 1471, 1383, 1348, 1126, 1017, 1000, 853, 787, 
722. 19F NMR (376 MHz, CDCl3) δ -168.7. HRMS (ESI, m/z): calcd. for C25H21FN4NaO5 
(M+Na)+: 499.1394, found: 499.1384. 
 2-(1,3-Dioxoisoindolin-2-yl)-3-fluoro-3-(naphthalen-2-yl)-N-(2-(pyridin-2-
yl)propan-2-yl)propanamide (3.2l). White solid, 76.6 mg, 53% yield, with 0.3 
equivalents of Fe(OAc)2 and 300 µL of iPrCN. 1H NMR (400 MHz, CDCl3) δ 1H NMR 
(400 MHz, CDCl3) δ 8.90 (d, J = 7.2 Hz, 1H), 8.55 (d, J = 4.4 Hz, 1H), 7.92 (s, 1H), 7.84-
7.75 (m, 4H), 7.70-7.68 (m, 2H), 7.62-7.57 (m, 3H), 7.49-7.46 (m, 3H), 7.23 (dd, J = 7.2, 






1.84 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.45, 164.93 (d, J = 2.0 Hz), 163.56, 147.02, 
138.21, 134.00, 133.79 (d, J = 2.0 Hz), 132.80 (d, J = 19.0 Hz), 132.75, 131.50, 128.81, 
128.40, 127.92 (d, J = 7.0 Hz), 127.68, 126.85, 126.38, 123.61 (d, J = 4.0 Hz), 123.52, 
122.30, 119.89, 92.23 (d, J = 169.0 Hz), 57.29, 56.57 (d, J = 36.0 Hz), 27.53. IR (KBr) ῡ 
(cm-1) 3315, 3058, 2979, 2930, 1778, 1716, 1682, 1514, 1471, 1385, 1266, 1127, 997, 
751,723, 553. 19F NMR (376 MHz, CDCl3) δ -162.6. HRMS (ESI, m/z): calcd. for 
C29H24FN3NaO3 (M+Na)+: 504.1691, found:504.1699. 
 3-Fluoro-N-(2-(pyridin-2-yl)propan-2-yl)butanamide (3.4a). Colorless oil, 54.5 
mg, 81% yield, with 0.75 equivalents of Fe(OAc)2 and 400 µL of MeCN. 1H NMR (500 
MHz, CDCl3) δ 8.53-8.49 (m, 1H), 7.88 (br s, 1H), 7.74-7.69 (m, 1H), 7.40 (d, J = 8.0 Hz, 
1H), 7.21-7.17 (m, 1H), 5.22-5.05 (m, 1H), 2.70-2.60 (m, 1H), 2.55-2.43 (m, 1H), 1.76 (s, 
3H), 1.76 (s, 3H), 1.43 (dd, J = 24.0, 6.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 168.39, 
164.36, 147.65, 137.09, 121.87, 119.42, 88.16 (d, J = 164.8 Hz), 56.72, 45.33 (d, J = 17.8 
Hz), 27.51, 27.48, 20.88 (d, J = 22.0 Hz). IR (neat) ῡ (cm-1) 3318, 3063, 2981, 2934, 2872, 
1737, 1651, 1591, 1538, 1383, 1319, 1230, 1128, 1058, 994, 926, 837, 788, 749, 700. 19F 
NMR (470 MHz, CDCl3) δ -172.1 (m, 1F). HRMS (ESI, m/z): calcd. for C12H18FN2O 
(M+H)+: 225.1403, found: 225.1406. 
 3-Fluoro-N-(2-(pyridin-2-yl)propan-2-yl)tetradecanamide (3.4b). White solid, 
87.5 mg, 80% yield, with 0.75 equivalents of Fe(OAc)2 and 400 µL of MeCN. 1H NMR 
(500 MHz, CDCl3) δ 8.53-8.49 (m, 1H), 7.83 (br s, 1H), 7.73-7.66 (m, 1H), 7.40 (d, J = 
8.0 Hz, 1H), 7.21-7.15 (m, 1H), 5.05-4.87 (m, 1H), 2.65-2.40 (m, 2H), 1.82-1.55 (m, 8H), 
1.53-1.15 (m, 18 H), 0.92-0.85 (m, 3H). 13C NMR (125 MHz, CDCl3) δ 168.62 (d, J = 4.4 






22.5 Hz), 35.03 (d, J = 20.4), 29.65, 29.63, 29.55, 29.50, 29.37, 29.35, 27.55, 27.51, 24.97 
(d, J = 4.3 Hz), 22.69, 14.10. IR (neat) ῡ (cm-1) 3318, 3064, 2923, 2853, 1651, 1591, 1545, 
1473, 1431, 1579, 1206, 1127, 1048, 993, 786, 747, 74. 19F NMR (470 MHz, CDCl3) δ -
179.1 (m, 1F). HRMS (ESI, m/z): calcd. for C22H38FN2O (M+H)+: 365.2968, found: 
365.2974. 
 3-Cyclopentyl-3-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)propanamide (3.4c). 
White solid, 62.6 mg, 75% yield, with 0.75 equivalents of Fe(OAc)2 and 400 µL of MeCN. 
1H NMR (500 MHz, CDCl3) δ 8.53-8.49 (m, 1H), 7.83 (br s, 1H), 7.73-7.66 (m, 1H), 7.40 
(d, J = 8.0 Hz, 1H), 7.20-7.15 (m, 1H), 4.87-4.72 (m, 1H), 2.62-2.45 (m, 2H), 2.17-2.04 
(m, 1H), 1.85-1.45 (m, 13H), 1.35-1.23 (m, 1H). 13C NMR (125 MHz, CDCl3) δ 168.85 (d, 
J = 2.0 Hz), 164.42, 147.68, 137.06, 121.83, 119.43, 94.53 (d, J = 169.4 Hz), 56.76, 44.07 
(d, J = 19.1 Hz), 43.06 (d, J = 22.9 Hz), 28.52 (d, J = 6.4 Hz), 28.07 (d, J = 3.3 Hz), 27.55, 
27.49, 25.64, 25.61. IR (neat) ῡ (cm-1) 3317, 3062, 2956, 2869, 1651, 1591, 1544, 1474, 
1431, 1380, 1207, 1127, 1048, 1023, 995, 857, 787, 748, 622. 19F NMR (470 MHz, CDCl3) 
δ -180.3 (m, 1F). HRMS (ESI, m/z): calcd. for C16H24FN2O (M+H)+: 225.1873, found: 
279.1867. 
 3-Fluoro-4-phenyl-N-(2-(pyridin-2-yl)propan-2-yl)butanamide (3.4d). White 
solid, 82.0 mg, 91% yield, with 0.75 equivalents of Fe(OAc)2 and 400 µL of MeCN. 1H 
NMR (500 MHz, CDCl3) δ 8.50 (d, J = 5.0 Hz, 1H), 7.82 (br s, 1H), 7.73-7.68 (m, 1H), 
7.39 (d, J = 8.0 Hz, 1H), 7.33-7.22 (m, 5H), 7.21-7.16 (m, 1H), 5.28-5.12 (m, 1H), 3.03 
(dd, J = 23.0, 6.0 Hz, 2H), 2.71-2.46 (m, 2H), 1.76 (s, 3H), 1.75 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 168.28, 164.29, 147.64, 137.10, 136.48, 129.59, 128.49, 126.76, 121.88, 






27.51, 27.47. IR (neat) ῡ (cm-1) 3318, 3062, 3029, 2926, 2855, 1653, 1591, 1543, 1512, 
1474, 1430, 1380, 1204, 1127, 1031, 997, 787, 748, 700. 19F NMR (470 MHz, CDCl3) δ -
188.9 (m, 1F). HRMS (ESI, m/z): calcd. for C18H22FN2O (M+H)+: 301.1716, found: 
301.1723. 
 3-Fluoro-5-phenyl-N-(2-(pyridin-2-yl)propan-2-yl)pentanamide (3.4e). White 
solid, 67.0 mg, 71% yield, with 3.0 equivalents. of Selectfluor, 0.75 equivalents of 
Fe(OAc)2 and 400 µL of MeCN. 1H NMR (500 MHz, CDCl3) δ 8.52-8.49 (m, 1H), 7.87 
(br s, 1H), 7.73-7.67 (m, 1H), 7.41-7.38 (m, 1H), 7.30-7.25 (m, 2H), 7.22-7.16 (m, 4H), 
5.08-4.92 (m, 1H), 2.89-2.43 (m, 4H), 2.11-1.86 (m, 2H), 1.76 (s, 3H), 1.75 (s, 3H). 13C 
NMR (125 MHz, CDCl3) δ 168.30 (d, J = 4.6 Hz), 164.31, 147.64, 141.17, 137.09, 128.48, 
128.44, 126.04, 121.88, 119.42, 90.70 (d, J = 168.0 Hz), 56.73, 43.76 (d, J = 22.5 Hz), 
36.78 (d, J = 20.8 Hz), 31.26 (d, J = 4.4 Hz), 27.48. IR (neat) ῡ (cm-1) 3309, 2964, 2926, 
2852, 1645, 1592, 1537, 1471, 1429, 1274, 1127, 956, 787, 749, 622. 19F NMR (470 MHz, 
CDCl3) δ -180.9 (m, 1F). HRMS (ESI, m/z): calcd. for C19H24FN2O (M+H)+: 315.1873, 
found: 315.1876. 
 3-Fluoro-3-phenyl-N-(2-(pyridin-2-yl)propan-2-yl)propanamide (3.4f). White 
solid, 61.8 mg, 72% yield, with 0.2 equivalents of Fe(OAc)2 and 400 µL of MeCN. 1H 
NMR (500 MHz, CDCl3) δ 8.51-8.48 (m, 1H), 7.89 (br s, 1H), 7.72-7.67 (m, 1H), 7.41-
7.30 (m, 6H), 7.20-7.16 (m, 1H), 5.99 (ddd, J = 47.0, 9.0, 4.0 Hz, 1H), 2.99-2.90 (m, 1H), 
2.79-2.66 (m, 1H), 1.77 (s, 3H), 1.72 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 167. 80 (d, J 
= 4.1 Hz), 164.24, 147.59, 139.37 (d, J = 19.4 Hz), 137.10, 128.57, 128.53 (d, J = 1.5 Hz), 
125.52 (d, J = 6.9 Hz), 121.88, 119.41, 91.51 (d, J = 170.3 Hz), 56.79, 45.91 (d, J = 25.4 






1431, 1380, 1216, 1127, 1015, 994, 787, 748, 699. 19F NMR (470 MHz, CDCl3) δ -174.5 
(m, 1F). HRMS (ESI, m/z): calcd. for C17H20FN2O (M+H)+: 287.1560, found: 287.1554. 
 3-Fluoro-2-isopropyl-N-(2-(pyridin-2-yl)propan-2-yl)pentanamide (3.4g). 
White solid, 61.4 mg, 73% yield, with 0.75 equivalents of Fe(OAc)2 and 400 µL of MeCN. 
1H NMR (500 MHz, CDCl3) δ 8.53-8.50 (m, 1H), 7.86 (br s, 1H), 7.72-7.67 (m, 1H), 7.40 
(d, J = 8.0 Hz, 1H), 7.18-7.14 (m, 1H), 4.78-4.63 (m, 1H), 2.14-1.96 (m, 2H), 1.84 (m, 
8H), 1.07-0.99 (m, 9H). 13C NMR (125 MHz, CDCl3) δ 170.78, 164.67, 147.73, 136.86, 
121.70, 119.47, 94.08 (d, J = 170.9 Hz), 59.83 (d, J = 19 Hz), 56.61, 27.72 (d, J = 5.3 Hz), 
27.58, 27.27, 26.06 (d, J = 21.4 Hz), 20.84, 20.38, 9.97 (d, J = 5.5 Hz). IR (neat) ῡ (cm-1) 
3318, 3062, 3029, 2926, 2855, 1653, 1591, 1543, 1512, 1474, 1430, 1380, 1204, 1127, 
1031, 997, 787, 748, 700. 19F NMR (470 MHz, CDCl3) δ -190.8 (m, 1F). HRMS (ESI, m/z): 
calcd. for C16H26FN2O (M+H)+: 281.2029, found: 281.2031. 
 2-(Fluoro(phenyl)methyl)-3-methyl-N-(2-(pyridin-2-yl)propan-2-
yl)butanamide (3.4h). White solid, 53.2 mg, 54% yield, with no Fe(OAc)2 and 400 µL of 
MeCN. 1H NMR (500 MHz, CDCl3) δ 8.52-8.49 (m, 1H), 7.85 (br s, 1H), 7.69-7.64 (m, 
1H), 7.43-7.28 (m, 6H), 7.19-7.15 (m, 1H), 5.82 (dd, J = 46.0, 7.5 Hz, 1H), 2.57-2.48 (m, 
1H), 1.85-1.63 (m, 7H), 1.07-0.93 (m, 6H). 13C NMR (125 MHz, CDCl3) δ 169.75, 164.56, 
147.56, 138.16 (d, J = 19.9 Hz), 136.94, 128.57 (d, J = 1.5 Hz), 128.45, 128.46 (d, J = 6.4 
Hz), 121.71, 119.47, 93.86 (d, J = 171.0 Hz), 60.27 (d, J = 21.8 Hz), 56.77, 27.59 (d, J = 
6.5 Hz), 27.55, 27.28, 21.61, 19.06. IR (neat) ῡ (cm-1) 3339, 3062, 2965, 2932, 2873, 1743, 
1668, 1592, 1508, 1473, 1454, 1379, 1218, 1127, 1049, 995, 864, 787, 749, 700. 19F NMR 
(470 MHz, CDCl3) δ -176.9 (m, 1F). HRMS (ESI, m/z): calcd. for C20H26FN2O (M+H)+: 







yl)butanamide (3.4i). White solid, 68.3 mg, 71% yield, with 0.75 equivalents of Fe(OAc)2 
and 400 µL of MeCN. 1H NMR (500 MHz, CDCl3) δ 8.54-8.50 (m, 1H), 7.84 (br s, 1H), 
7.72-7.66 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.19-7.15 (m, 1H), 4.81-4.66 (m, 1H), 2.14-
2.03 (m, 1H), 1.96-1.90 (m, 1H), 1.82-1.60 (m, 13H), 1.36-0.97 (m, 8H). 13C NMR (125 
MHz, CDCl3) δ 170.78, 164.68, 147.73, 136.85, 121.70, 119.48, 93.49 (d, J = 170.9 Hz), 
58.89 (d, J = 19.0 Hz), 56.63, 37.03 (d, J = 4.8 Hz), 31.10, 30.57, 27.63, 27.32, 26.40, 
26.26 (2C), 26.08, 25.91, 9.98 (d, J = 5.5 Hz). IR (neat) ῡ (cm-1) 3309, 2964, 2926, 2852, 
1645, 1592, 1537, 1477, 1429, 1274, 1127, 956, 787, 749, 622. 19F NMR (470 MHz, CDCl3) 
δ -190.5 (m, 1F). HRMS (ESI, m/z): calcd. for C19H30FN2O (M+H)+: 321.2342, found: 
321.2340. 
 2-Cyclohexyl-3-fluoro-3-phenyl-N-(2-(pyridin-2-yl)propan-2-yl)propanamide 
(3.4j). White solid, 66.3 mg, 60% yield, with no Fe(OAc)2 and 400 µL of MeCN. 1H NMR 
(500 MHz, CDCl3) δ 8.53-8.50 (m, 1H), 7.82 (br s, 1H), 7.68-7.64 (m, 1H), 7.41-7.28 (m, 
6H), 7.18-7.15 (m, 1H), 5.86 (dd, J = 46.0, 7.5 Hz, 1H), 2.54 (dt, J = 20.0, 7.0 Hz, 1H), 
1.80-1.43 (m, 12H), 1.30-1.00 (m, 5H). 13C NMR (125 MHz, CDCl3) δ 169.84, 164.56, 
147.56, 138.28 (d, J = 19.9 Hz), 136.92, 128.47 (d, J = 1.5 Hz), 128.41, 126.33 (d, J = 6.8 
Hz), 121.69, 119.47, 93.28 (d, J = 171.5 Hz), 60.00 (d, J = 21.9 Hz), 56.75, 37.22 (d, J = 
5.8 Hz), 31.85, 29.65, 27.54, 27.32, 26.43, 26.29. IR (neat) ῡ (cm-1) 3337, 3062, 2928, 
2852, 1740, 1688, 1654, 1592, 1508, 1473, 1450, 1431, 1378, 1216, 1126, 1066, 994, 968, 
786, 747, 699. 19F NMR (470 MHz, CDCl3) δ -178.2 (m, 1F). HRMS (ESI, m/z): calcd. for 






 3-Fluoro-2-phenyl-N-(2-(pyridin-2-yl)propan-2-yl)butanamide (3.4k + 3.4k’), 
66.7 mg, 74% yield (d.r. = 5:1), with 0.5 equivalents of Fe(OAc)2 and 400 µL of MeCN. 
Compound 3.4k: white solid; 1H NMR (500 MHz, CDCl3) δ 8.49-8.46 (m, 1H), 7.92 (br s, 
1H), 7.69-7.64 (m, 1H), 7.43-7.39 (m, 2H), 7.35-7.27 (m, 4H), 7.18-7.14 (m, 1H), 5.40-
5.24 (m, 1H), 3.56 (dd, J = 11.0, 9.0 Hz, 1H), 1.77 (s, 3H), 1.66 (s, 3H), 1.21 (dd, J = 24.0, 
6.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 169.72, 164.33, 147.53, 137.01, 136.20 (d, J 
= 10.0 Hz), 128.74, 128.46, 127.65, 121.77, 119.37, 91.34 (d, J = 169.3 Hz), 60.57 (d, J 
= 22.5 Hz), 56.77, 27.55, 27.31, 18.87 (d, J = 22.0 Hz). IR (neat) ῡ (cm-1) 3326, 3061, 
2862, 2933, 1659, 1592, 1539, 1506, 1474, 1381, 1266, 1127, 1078, 994, 868, 786, 748, 
700. 19F NMR (470 MHz, CDCl3) δ -171.3 (m, 1F). HRMS (ESI, m/z): calcd. for 
C18H22FN2O (M+H)+: 301.1716, found: 301.1703. 
 3-Fluoro-2-(naphthalen-1-yl)-N-(2-(pyridin-2-yl)propan-2-yl)butanamide 
(3.4l). White solid, 75.7 mg,: 72% yield, with 0.75 equivalents of Fe(OAc)2 and 400 µL of 
MeCN. 1H NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 8.50-8.48 (m, 1H), 
8.03 (s, 1H), 7.93 (s, 1H), 7.88-7.83 (m, 3H), 7.68 (td, J = 7.6, 1.6 Hz, 1H), 7.59 (dd, J = 
8.4, 1.6 Hz, 1H), 7.53-7.47 (m, 2H), 7.36 (d, J = 8.4 Hz, 1H), 7.20-7.17 (m, 1H), 5.56-5.38 
(m, 1H), 3.78 (dd, J = 10.8, 9.2 Hz, 1H), 1.81 (s, 3H), 1.69 (s, 3H), 1.26 (dd, J = 24.4, 6.4 
Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 169.81 (d, J = 2.0 Hz), 164.10, 147.19, 137.45, 
133.65 (d, J = 2.0 Hz), 133.45, 132.84, 128.46, 127.95, 127.63, 127.49, 126.32, 126.21, 
126.02, 121.93, 119.59 , 91.37 (d, J = 169.0 Hz), 60.52 (d, J = 23.0 Hz), 56.73, 27.45 (d, 
J = 18.0 Hz), 18.99 (d, J = 21.0 Hz). IR (KBr) ῡ (cm-1) 3325, 3056, 2981, 2932, 1718, 
1661, 1508, 1382, 1132, 1074, 790, 750. 19F NMR (376 MHz, CDCl3) δ -171.0. HRMS 






 Deprotection of product 3.2g. To a 35 mL oven-dried pressure tube, 3.2g (129.3g, 
0.3 mmol, 1.0 equiv) and hydrazine hydrate (30.0 mg, 0.6 mmol, 2.0 equiv) were dissolved 
in 2 mL of MeOH. The tube was then sealed and stirred at 65 o C for 10 h. After the reaction, 
the solvent was removed. The crude product was dissolved in 20 mL DCM, and 
undissolved solid was filtered. The filtrate was concentrated in vacuo, and the residue was 
purified by flash chromatography on silica gel to yield the desired product 3.5. Colorless 
oil, 82.3 mg, 91% yield. 1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 8.50 (d, J = 4.4 Hz, 
1H), 7.70 – 7. 66 (m, 1H), 7.41 – 7.30 (m, 6H), 7.17 (dd, J = 7.2, 5.2 Hz, 1H), 6.23 (dd, J 
= 45.2, 4.0 Hz, 1H), 4.01 (dd, J = 12.4, 4.0 Hz, 1H), 1.70 (s, 3H), 1.74 (s, 3H), 1.60 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ 169.56 (d, J = 11.1 Hz), 164.36, 147.96, 136.84, 135.47 (d, 
J = 21.0 Hz), 128.50, 128.33, 126.21 (d, J = 8.4 Hz), 121.74, 119.32, 93.89 (d, J = 173.5 
Hz), 60.04 (d, J = 25.9 Hz), 56.48, 27.46, 27.25. 19F NMR (376 MHz, CDCl3) -188.33. IR 
(KBr) ῡ (cm-1) 3312, 3291, 3063, 2980, 2933, 1667, 1511, 1474, 1126, 913, 747, 705, 557 
cm-1. HRMS (ESI, m/z): calcd. for C17H19FN3O (M-H)-: 300.1518, found: 300.1531. 
 Cleavage of directing group. To a solution of 3.2g (129 mg, 0.3 mmol) in acetic 
acid (0.5 mL) mixed with acetic anhydride (2.5 mL) in -15 oC was slowly added NaNO2 
(420 mg, 6.2 mmol) in portions over 1.5 hour. After stirring for 3 days at -15 oC, the 
reaction was poured into a mixture of ice and water. The mixture was extracted with cold 
ether. The organic phase was then washed with icy water for 4 times and dried with 
anhydrous Na2SO4 in an ice bath. The solvent was removed under reduce pressure at 0 oC. 
The residue was dissolved in THF (5 mL) mixed with H2O (2 mL) and cooled to -15 oC. 
Then H2O2 (30% in water, 0.6 ml), followed by lithium hydroxide (144 mg, 6.0 mmol) was 






another 3 hours. Finally, the mixture was treated with aqueous Na2SO3 (170 mg in 2 mL 
H2O), followed by acidification with HCl (1M) to pH 2-3. The mixture was extracted with 
ether and the organic layer was then washed with brine, dried over anhydrous Na2SO4. The 
filtrate was concentrated in vacuo, and the residue was purified by flash chromatography 
on silica gel to yield the desired product 3.6. Yellow solid, 61.1 mg 65% yield. 1H NMR 
(400 MHz, CDCl3) 7.76 – 7.67 (m, 4H), 7.34 (d, J = 4.8 Hz, 2H), 7.25 – 7.24 (m, 3H), 6.37 
(dd, J = 46.6, 8.4 Hz, 1H), 5.34 (dd, J = 15.4, 8.4 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 
171.38, 166.55, 134.99 (d, J = 19.6 Hz), 134.36, 131.15, 129.57 (d, J = 1.9 Hz), 128.48, 
126.92 (d, J = 5.6 Hz), 123.70, 90.53 (d, J = 177.5 Hz), 54.50 (d, J = 35.6 Hz). 19F NMR 
(376 MHz, CDCl3) -170.11. IR (KBr) ῡ (cm-1) 3005, 2989, 1778, 1717, 1471, 1391, 1275, 
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CHAPTER 4. SYNTHESIS OF CINNOLINES VIA COPPER-CATALYZED 
AEROBIC DEHYDROGENATIVE CYCLIZATION OF N-METHYL-N-
PHENYLHYDRAZONES 
(Reproduced in part with permission from Zhang, G.-W.; Miao, J.-M.; Zhao, Y.; Ge, H.-
B. “Synthesis of Cinnolines via Copper-Catalyzed Aerobic Dehydrogenative Cyclization 
of N-Methyl-N-phenylhydrazones”, Angew. Chem. Int. Ed. 2012, 51, 8318-8321. 





 Selective carbon-carbon (C-C) bond formation is one of the most important 
processes in organic chemistry since it enables key steps in the synthesis of complex 
organic molecules from simple precursors. Traditionally, the construction of C-C bonds 
relies primarily on prefunctionalized substrates, which usually requires additional synthetic 
steps, and thus reduces the overall efficiency of this transformation.1 For this reason, C-C 
bond forming reactions through transition-metal-catalyzed direct functionalization of 
relatively unreactive C-H bonds have emerged as a major topic of research in organic 
chemistry.2 Among them, copper-catalyzed aerobic dehydrogenative coupling reactions 
from two carbon-hydrogen (C-H) bonds have received a renewed interest in recent years 
with the following inherent advantages: maximizing atom economy by avoiding 






with molecular oxygen as the sole oxidant.3 Since the discovery of the over 140 years old 
Glaser reaction, the oxidative dimerization of terminal alkynes,4 many efforts have been 
devoted into this field to construct new C-C bonds and a number of copper-catalyzed 
aerobic dehydrogenative coupling reactions via an sp or sp2 C-H bond functionalization 
process have been developed, including oxidative dimerization of phenols,5 naphthols6 and 
electron-deficient arenes,7 cross-coupling of terminal alkynes with electron-deficient 
arenes,8 and intramolecular dehydrogenative cyclization of anilides.9 In comparison, the 
development of copper-catalyzed aerobic dehydrogenative coupling on sp3 carbons is still 
in its infancy and the current advances suffer severely from the restricted substrate scope, 
namely only substrates with the sp3 carbon adjacent to a heteroatom10 or malonic amide 
derivatives.11 During our investigation of transition-metal-catalyzed coupling reactions 
including the synthesis of pyrazolines from hydrazones,12 N-methyl-N-phenylhydrazones 
were discovered as unprecedented substrates for copper-catalyzed aerobic intramolecular 
dehydrogenative cyclization for the formation of cinnolines, a privileged structure in 
medicines, and many medicinal compounds with a broad range of biological activities 
including antibacterial, anti-cancer, antifungal, antihypertensive, antiinflammatory, and 
anti-ulcer activities.13 
 
4.2 Results and Discussion 
 Our investigation began with the oxidative cyclization of 1-methyl-1-phenyl-2-(1-
phenylethylidene)hydrazine (4.1a) with catalytic CuSO4 in the presence of 1 atm O2. To 






albeit in low yields (Table 4.1, entries 1-3). The following extensive catalyst screening 
showed that although other CuII and CuI sources could catalyze the cyclization of 4.1a, 
none of these catalysts improved the yield (entries 8-16).  Subsequently, a series of 
nucleophilic bases, such as pyridine, DMAP, and DABCO, were screened. However, none 
of these bases improved the yield. Interestingly, the yield was increased by the addition of 
an acid along with excess pyridine, and the optimal results were obtained with 1 equivalent 
of CF3SO3H and 3.5 equivalent of pyridine (entry 22). It is worth mentioning that the 
methyl group on the nitrogen is required for this reaction since 1-phenyl-2-(1-
phenylethylidene)hydrazine gave less than 10% yield of the desired product due to the 
decomposition of the starting material under the current reaction conditions. 
 
Table 4.1 Optimization of Reaction Conditions for Cinnolines Synthesisa 
 
Entry Cu Source Additive Solvents Yield (%)b 
1 CuSO4 (20) - DMF 37 
2 CuSO4 (20) - DMA 32 
3 CuSO4 (20) - CH3CN 30 
4 CuSO4 (20) - DMSO <5 
5 CuSO4 (20) - NMP trace 
6 CuSO4 (20) - DMF trace 
7 - - DMF 0 
8 Cu(OAc)2 (20) - DMF 22 






  Table 4.1 continued. 
10 CuCl2 (20) - DMF 19 
11 CuF2 (20) - DMF 17 
12 Cu(OH)2CO3 (20) - DMF 16 
13 CuI (20) - DMF 15 
14 CuBr·DMS (20) - DMF 12 
15 CuSO4 (20) - DMF 25 
16 CuSO4 (20) - DMF 22 
17 CuSO4 (20) Py (3.5)/CF3SO3H (1) DMF 73 
18 CuSO4 (20) Py (3.5)/TsOH (1) DMF 55 
19 CuSO4 (10)/    
CuI (10) 
Py (3.5)/CF3CO2H (1) DMF 47 
20 CuSO4 (10)/    
CuI (10) 
Py (3.5)/AcOH (1) DMF 43 
21 CuSO4 (10)/    
CuI (10) 
Py (3.5)/PhCO2H (1) DMF 42 
22 CuSO4 (1.5)/    
CuI (7.5) 
Py (3.5)/CF3CO2H (1) DMF 83(80)b 
23 CuSO4 (1.5)/    
CuI (5) 
Py (3.5)/CF3CO2H (1) DMF 70 
24 CuSO4 (1.5)/    
CuI (7.5) 
Py (3.5)/CF3CO2H (1) DMF 20 
a Conditions: 4.1a (0.3 mmol), Cu source, additive, O2 (1 atm), 3 mL of solvent, 110 °C, 
14 h unless otherwise noted. b Isolated yields. c Under air. 
 
 As shown in Scheme 4.1, this transformation is compatible with electron-rich and 
electron-deficient N-phenyl ring (Scheme 4.1, 4.2b-o). There is no apparent electronic or 
steric effect on this ring, and good to high yields of products were obtained with either an 
electron-donating or electron-withdrawing group substituted substrate on the p-, m-, or o-
position. It was noted that the m-OMe, Me, or Br substituted substrates gave a mixture of 
p- and o-products (4.2h-j), favoring the p-products while the more hindered iPr group and 






products (4.2k and 4.2l). As expected, halogens (F, Cl, and Br) were tolerated under the 
current reaction system, allowing for the further manipulation of the initial products.  
Scheme 4.1 Scope of N-Methyl-N-phenylhydrazones (1)a,b.  a Conditions: 4.1 (0.3 mmol), 
CuSO4 (1.5 mol%), CuI (7.5 mol%), Py (3.5 eq), CF3SO3H (1.0 eq), O2 (1 atm), 3 mL of 
DMF, 110 °C, 14 h unless otherwise noted. b Isolated yields. c The reaction was run at 
150 °C for 20 h. d The reaction was run at 95 °C for 48 h. 
 
 In contrast, there is an electronic effect on the other phenyl ring (Scheme 4.2, 4.2q-
z). Generally, strong electron-donating groups on this ring provide higher yields than 
strong electron-withdrawing groups. It should be mentioned that replacement of this phenyl 
group with an alkyl group gave only trace amount of product, due to the decomposition of 






was completely prohibited with the introduction of an alkyl group on the α-carbon to the 
imine moiety (4.2ac). 
Scheme 4.2 Scope of N-Methyl-N-phenylhydrazones (2)a,b.  a Conditions: 1 (0.3 mmol), 
CuSO4 (1.5 mol%), CuI (7.5 mol%), Py (3.5 eq), CF3SO3H (1.0 eq), O2 (1 atm), 3 mL of 
DMF, 110 °C, 14 h unless otherwise noted. b Isolated yields. c The reaction was run at 
150 °C for 20 h. d The reaction was run at 95 °C for 48h. 
 
 It is noteworthy that a small amount of 2-(N-methyl-N-phenylhydrazono)-2-
phenylacetaldehyde (4.3) was isolated along with the desired product 4.2a from the 
reaction of 1-methyl-1-phenyl-2-(1-phenylethylidene)hydrazine (4.1a) under the current 
reaction conditions. Furthermore, treatment of 4.3 under the cyclization reaction conditions 







Scheme 4.3. Cyclization of 2-(N-Methyl-N-phenylhydrazono)-2-phenylacetaldehyde 
 
To further probe the reaction mechanism, deuterium-labeling experiments were 
conducted (Scheme 4.4). No significant kinetic isotope effect was observed in the 
reaction of [D1]-1a, thus suggesting that the arene C(sp2)-H bond cleavage might not be 
involved in the rate-determining step.14 
 
 
Scheme 4.4. Deuterium-Labeling Experiments 
 
 Based on the above observation, the cyclization reaction mechanism of N-methyl-
N-phenyl-2-(1-phenylethylidene)hydrazine (4.1a) is proposed (Scheme 4.5). It is believed 
that this transformation starts with the oxidation of 4.1a into 2-(N-Methyl-N-
phenylhydrazono)-2-phenylacetaldehyde (4.3) through a copper-catalyzed process in the 
presence of oxygen.15 Copper-assisted Freidel-Crafts-type cyclization of 4.3 generates the 
intermediate VII. Activation of VII by a copper species, followed by the loss of the 
hydroxyl group and subsequent methyl group by nucleophilic substitution of iodine 






Scheme 4.5 Proposed Mechanism for Cinnoline Synthesis. 
 
4.3 Summary 
 In summary, an efficient Cu-catalyzed aerobic dehydrogenative intramolecular 
cyclization reaction of N-methyl-N-phenylhydrazones has been developed via a 
sequential sp3 C-H oxidation, cyclization, and aromatization process. This transformation 
is the first example of copper-catalyzed coupling reactions of hydrazones via a sp3 C-H 




 General Methods. All the solvents and commercially available reagents were 






(w/h F254, Dynamic Adsorbents Inc, 0.25 mm thick) were used; for air-flashed column 
chromatography, Flash Silica Gel (Dynamic Adsorbents Inc, 32-63 μm) was used. The 1H 
and 13C NMR spectra were obtained on a Bruker 500 MHz NMR Fourier transform 
spectrometer. 1H NMR data was reported as: chemical shift (δ ppm), multiplicity, coupling 
constant (Hz), and integration. 13C NMR data was reported in terms of chemical shift (δ 
ppm), multiplicity, and coupling constant (Hz). The infrared spectra were obtained using a 
Thermo Nicolet IR 330 Spectrometer. Mass (MS) analysis was obtained using Agilent 
1100 series LC/MSD system with Electrospray Ionization (ESI). 
 General procedure for the preparation of N-methyl-N-phenylhydrazones 4.1a-
4.1e, 4.1g-4.1k, 4.1m-4.1n, and 4.1p-4.1ab16,17: 
A 250 mL three-necked flask was charged with 50 mL anhydrous ethanol, ketone (20 
mmol), acyl hydrazine (25 mmol) and acetic acid (114.4 µL, 2 mmol). The reaction mixture 
was then refluxed for 2-4 h (monitored by TLC). After removal of ethanol, the residue was 
dissolved in ethyl acetate (100 mL), washed with a mixture of acetic acid (100 mL) and 
water (100 mL), and the organic phase was dried over Na2SO4 and concentrated under 
vacuum. The hydrazone, which was usually obtained in nearly quantitative yield, was used 
directly for the next step without further purification. 
 To a solution of hydrazone (5 mmol) in dry THF (20 mL) was added NaH (95%, 
1.2 g, 47.5 mmol) at 0 °C. The mixture was stirred for 15 min, and then methyl iodide (7.5 
mmol) was added dropwise. After stirring at room temperature for 3 h, the reaction mixture 
was refluxed for another 2 h. The reaction mixture was cooled to the room temperature, 
and then the solvent was removed under reduced pressure. The residue was diluted with 






the solvent, the residue was purified by flash chromatography column on silica gel 
(gradient eluent of EtOAc in hexanes: 1 ~ 5%, v/v) to yield the product 1 as a yellow oil. 
 1-Methyl-2-(1-phenylethylidene)-1-(p-tolyl)hydrazine (4.1b). Yellow oil, yield: 
85% (from ketone). 1H NMR (500 MHz, CDCl3, a mixture of (Z/E) isomers in ratio ca. 
4.3:1, the minor isomer is marked with an *) δ: 2.28 (s, 3H), 2.31 (s, 3H), 3.15 (s, 3H), 6.88 
(d, J = 5.0 Hz, 2H), 7.08 (d, J = 5.0 Hz, 2H), 7.40-7.41 (m, 3H), 7.88-7.91 (m, 2H); 1.75* 
(s, 3H), 2.41* (s, 3H), 3.40* (s, 3H), 7.23-7.38* (m, 5H), 7.54* (d, J = 5.0 Hz, 2H), 7.72* 
(d, J = 5.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.4, 20.5, 43.5, 116.1, 122.6, 126.6, 
128.3, 129.4, 129.6, 138.4, 149.4, 164.6; 21.4*, 24.5*, 51.8*, 116.1*, 126.7*, 127.8*, 
128.3*, 129.6*, 141.3*, 141.5*, 149.8*, 164.6*; IR (neat) ῡ (cm-1) 3050, 2953, 1510, 1493, 
1457, 1376, 1363, 1309, 1095, 1070, 819, 760; MS (ESI): m/z = 239.3 [M + H+]. 
 1-(4-Fluorophenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1c). Yellow 
oil, yield: 91% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.32 (s, 3H), 3.10 (s, 3H), 
6.91-6.99 (m, 4H), 7.40-7.41 (m, 3H), 7.87-7.89 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 
16.4, 43.4, 115.3 (d, JCF = 21.2 Hz), 117.1 (d, JCF = 7.5 Hz), 126.6 (d, JCF = 10.0 Hz), 128.3, 
129.8, 138.2, 148.1, 157.5 (d, JCF = 236.2 Hz), 165.1; IR (neat) ῡ (cm-1) 3054, 2963, 2874, 
1608, 1505, 1445, 1364, 1223, 1101, 827; MS (ESI): m/z = 243.3 [M + H+]. 
 1-(4-Chlorophenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1d). Yellow 
oil, yield: 83% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.36 (s, 3H), 3.14 (s, 3H), 
6.89 (d, J = 10.0 Hz, 2H), 7.22 (d, J = 10.0 Hz, 2H), 7.42-7.43 (m, 3H), 7.89-7.91 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ: 16.5, 42.5, 116.5, 124.8, 126.6, 128.4, 128.6, 130.0, 138.0, 
149.9, 165.9; IR (neat) ῡ (cm-1) 3059, 2963, 2875, 1593, 1490, 1445, 1315, 1098, 1069, 






 1-(4-Bromophenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1e). Yellow 
oil, yield: 76% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.26 (s, 3H), 3.04 (s, 3H), 
6.74-6.75 (m, 2H), 7.26-7.28 (m, 2H), 7.32-7.35 (m, 3H), 7.80-7.82 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ: 15.5, 41.3, 111.2, 115.8, 125.6, 127.4, 129.0, 130.5, 136.9, 149.2, 
165.0; IR (neat) ῡ (cm-1) 3058, 2962, 2874, 1588, 1487, 1315, 1097, 1074, 819; MS (ESI): 
m/z = 305.3 [M + H+]. 
 1-Methyl-2-(1-phenylethylidene)-1-(4-(trifluoromethyl)phenyl)hydrazine 
(4.1g). Yellow oil, yield: 95% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.38 (s, 3H), 
3.20 (s, 3H), 6.96 (d, J = 10.0 Hz, 2H), 7.42-7.46 (m, 3H), 7.50 (d, J = 10.0 Hz, 2H), 7.92-
7.94 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.6, 41.6, 116.5, 120.9 (q, JCF = 32.5 Hz), 
125.0 (q, JCF = 268.7 Hz), 126.1 (q, JCF = 3.7 Hz), 126.8, 128.5, 130.3, 137.7, 153.1, 167.3; 
IR (neat) ῡ (cm-1) 3058, 2965, 2881, 1613, 1577, 1519, 1325, 1160, 1111, 1068, 830, 761; 
MS (ESI): m/z = 293.3 [M + H+]. 
 1-(3-Methoxyphenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1h). 
Yellow oil, yield: 79% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.36 (s, 3H), 3.16 (s, 
3H), 3.79 (s, 3H), 6.46-6.48 (m, 1H), 6.54-6.59 (m, 2H), 7.17-7.20 (m, 1H), 7.41-7.43 (m, 
3H), 7.90-7.92 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.9, 42.6, 55.1, 101.8, 106.0, 
108.1, 126.6, 128.3, 129.5, 129.8, 138.2, 152.6, 160.3, 165.6; IR (neat) ῡ (cm-1) 3059, 2997, 
2958, 2833, 1599, 1490, 1465, 1445, 1363, 1315, 1288, 1220, 1048, 994; MS (ESI): m/z = 
255.3 [M + H+]. 
 1-Methyl-2-(1-phenylethylidene)-1-(m-tolyl)hydrazine (4.1i). Yellow oil, yield: 
86% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.33 (s, 3H), 2.34 (s, 3H), 3.16 (s, 3H), 






(125 MHz, CDCl3) δ: 16.4, 21.8, 42.8, 112.6, 116.3, 120.9, 126.6, 128.3, 128.6, 129.7, 
138.3, 138.5, 151.3, 165.3; IR (neat) ῡ (cm-1) 3039, 2961, 2869, 1602, 1583, 1489, 1444, 
1315, 1101, 995; MS (ESI): m/z = 239.3 [M + H+]. 
 1-(3-Bromophenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1j). Yellow 
oil, yield: 85% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.37 (s, 3H), 3.14 (s, 3H), 
6.85-6.87 (m, 1H), 6.99-7.00 (m, 1H), 7.09-7.14 (m, 2H), 7.43-7.46 (m, 3H), 7.90-7.92 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ: 16.5, 42.1, 113.5, 117.9, 122.5, 122.9, 126.7, 128.4, 
130.0, 130.1, 137.9, 152.3, 166.7; IR (neat) ῡ (cm-1) 3061, 2965, 2874, 1588, 1558, 1477, 
1444, 1321, 1100, 986; MS (ESI): m/z = 305.4 [M + H+]. 
 1-(3-Isopropylphenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1k). 
Yellow oil, yield: 72% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 1.25 (d, J = 10.0 Hz, 
6 H), 2.34 (s, 3H), 2.83-2.90 (m, 1H), 3.17 (s, 3 H), 6.79-6.84 (m, 3H), 7.19-7.22 (m, 1H), 
7.41-7.43 (m, 3H), 7.90-7.92 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.6, 24.1, 34.5, 
42.9, 113.3, 114.0, 118.3, 126.7, 128.4, 128.8, 129.8, 138.4, 149.7, 151.4, 165.1; IR (neat) 
ῡ (cm-1) 3056, 2959, 2924, 2868, 1601, 1581, 1484, 1458, 1381, 1362, 1310, 1099, 1026, 
938, 774; MS (ESI): m/z = 267.3 [M + H+]. 
 1-(2-Methoxyphenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1m). 
Yellow oil, yield: 77% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 1.98 (s, 3H), 3.24 (s, 
3H), 3.94 (s, 3 H), 6.83-6.87 (m, 1H), 6.93-6.95 (m, 1H), 7.03-7.10 (m, 2H), 7.36-7.40 (m, 
3H), 7.77-7.79 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 17.0, 47.0, 55.6, 111.7, 121.1, 
121.4, 124.4, 126.3, 128.3, 129.0, 139.2, 142.5, 151.9, 160.0; IR (neat) ῡ (cm-1) 3059, 2960, 







 1-(2-Chlorophenyl)-1-methyl-2-(1-phenylethylidene)hydrazine (4.1n). Yellow 
oil, yield: 88% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.04 (s, 3H), 3.20 (s, 3H), 
7.00-7.03 (m, 1H), 7.15-7.18 (m, 1H), 7.24- 7.29 (m, 1H), 7.36-7.41 (m, 4H), 7.77-7.79 
(m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.9, 46.8, 123.2, 125.0, 126.5, 127.8, 128.4, 
128.5, 129.4, 130.6, 138.8, 150.9, 161.8; IR (neat) ῡ (cm-1) 3061, 2964, 2862, 1585, 1473, 
1443, 1273, 1050, 915, 757; MS (ESI): m/z = 260.5 [M + H+]. 
 1-Methyl-1-(naphthalen-1-yl)-2-(1-phenylethylidene)hydrazine (4.1p). Yellow 
oil, yield: 65% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 1.97 (s, 3H), 3.34 (s, 3H), 
7.28-7.30 (m, 1H), 7.33-7.41 (m, 4H), 7.49- 7.56 (m, 2H), 7.59 (d, J = 10.0 Hz, 1H), 7.80-
7.86 (m, 3H), 8.36 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 17.0, 48.8, 117.7, 
123.4, 124.4, 125.8, 125.9, 126.0, 126.4, 128.3 (2C), 128.6, 129.1, 134.8, 139.1, 151.0, 
160.4; IR (neat) ῡ (cm-1) 3055, 2960, 2878, 1592, 1573, 1493, 1461, 1445, 1388, 1332, 
1299, 1021, 1013, 913, 791; MS (ESI): m/z = 275.4 [M + H+]. 
 1-Methyl-1-phenyl-2-(1-(p-tolyl)ethylidene)hydrazine (4.1q). Yellow oil, yield: 
86% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.33 (s, 3H), 3.14 (s, 3H), 3.86 (s, 3H), 
6.87-6.90 (m, 1H), 6.93-6.95 (m, 4H), 7.25-7.28 (m, 2H), 7.89 (d, J = 10.0 Hz, 2H); 13C 
NMR (125 MHz, CDCl3) δ: 16.1, 42.6, 55.4, 113.7, 115.2, 119.7, 128.2, 128.8, 130.8, 
151.4, 161.1, 165.7; IR (neat) ῡ (cm-1) 3057, 3001, 2960, 2836, 1597, 1511, 1492, 1311, 
1253, 1176, 1029, 834; MS (ESI): m/z = 255.4 [M + H+]. 
 2-(1-(4-Methoxyphenyl)ethylidene)-1-methyl-1-phenylhydrazine (4.1r). 
Yellow oil, yield: 82% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.34 (s, 3H), 2.40 (s, 
3H), 3.15 (s, 3H), 6.87-6.96 (m, 3H), 7.22 (d, J = 5.0 Hz, 2H), 7.26-7.29 (m, 2H), 7.81 (d, 






128.9, 129.1, 135.5, 140.0, 151.4, 165.8; IR (neat) ῡ (cm-1) 3058, 2921, 1683, 1591, 1492, 
1314, 1096, 817; MS (ESI): m/z = 239.4 [M + H+]. 
 2-(1-(4-Fluorophenyl)ethylidene)-1-methyl-1-phenylhydrazine (4.1s). Yellow 
oil, yield: 95% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.32 (s, 3H), 3.15 (s, 3H), 
6.89-6.96 (m, 3H), 7.07-7.11 (m, 2H), 7.24-7.29 (m, 2H), 7.89-7.92 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ: 16.4, 42.7, 115.2 (d, JCF = 21.2 Hz), 115.5, 120.1, 128.5 (d, JCF = 8.7 
Hz), 128.8, 134.4 (d, JCF = 3.7 Hz), 151.2, 163.9 (d, JCF = 248.7 Hz), 164.3; IR (neat) ῡ 
(cm-1) 3061, 2962, 2873, 1598, 1540, 1508, 1405, 1313, 1158, 837; MS (ESI): m/z = 243.4 
[M + H+]. 
 2-(1-(4-Chlorophenyl)ethylidene)-1-methyl-1-phenylhydrazine (4.1t). Yellow 
oil, yield: 92% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.30 (s, 3H), 3.16 (s, 3H), 
6.89-6.96 (m, 3H), 7.28-7.29 (m, 2H), 7.37 (d, J = 10.0 Hz, 2H), 7.84 (d, J = 10.0 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ: 16.4, 42.9, 115.6, 120.2, 127.9, 128.5, 128.8, 135.8, 136.7, 
151.2, 163.7; IR (neat) ῡ (cm-1) 3059, 2918, 2873, 1598, 1579, 1465, 1398, 1278, 1179, 
1091, 1028, 995; MS (ESI): m/z = 260.3 [M + H+]. 
 2-(1-(4-Bromophenyl)ethylidene)-1-methyl-1-phenylhydrazine (4.1u). Yellow 
oil, yield: 86% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.30 (s, 3H), 3.16 (s, 3H), 
6.89-6.96 (m, 3H), 7.28-7.29 (m, 2H), 7.52 (d, J = 5.0 Hz, 2H), 7.77 (d, J = 5.0 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ: 16.4, 42.9, 115.6, 120.3, 124.1, 128.1, 128.8, 131.4, 137.1, 
151.2, 163.5; IR (neat) ῡ (cm-1) 3058, 3024, 2873, 1598, 1492, 1393, 1315, 1278, 1077, 
1008; MS (ESI): m/z = 304.1 [M + H+]. 
 4-(1-(2-Methyl-2-phenylhydrazono)ethyl)benzonitrile (4.1v). Yellow oil, yield: 






(m, 3H), 7.17-7.24 (m, 2H), 7.61 (d, J = 10.0 Hz, 2H), 7.92 (d, J = 10.0 Hz, 2H); 13C NMR 
(125 MHz, CDCl3) δ: 15.8, 42.7, 111.7, 115.1, 117.7, 119.9, 125.9, 127.9, 131.0, 141.5, 
150.0, 159.4; IR (neat) ῡ (cm-1) 3060, 2963, 2806, 1599, 1578, 1529, 1492, 1275, 1179, 
1028, 913; MS (ESI): m/z = 250.4 [M + H+]. 
 1-Methyl-1-phenyl-2-(1-(m-tolyl)ethylidene)hydrazine (4.1w). Yellow oil, yield: 
86% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.34 (s, 3H), 2.41 (s, 3H), 3.16 (s, 3H), 
6.89-6.97 (m, 3H), 7.23-7.32 (m, 4H), 7.67 (d, J = 10.0 Hz, 1H), 7.76 (s, 1H); 13C NMR 
(125 MHz, CDCl3) δ: 16.6, 21.4, 42.6, 115.4, 120.0, 123.9, 127.2, 128.2, 128.8, 130.6, 
138.0, 138.2, 151.2, 166.1; IR (neat) ῡ (cm-1) 3058, 2958, 2923, 1598, 1491, 1362, 1315, 
1096, 1071, 1028, 994, 752; MS (ESI): m/z = 239.4 [M + H+]. 
 1-Methyl-1-phenyl-2-(1-(3-(trifluoromethyl)phenyl)ethylidene)hydrazine 
(4.1x). Yellow oil, yield: 93% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.35 (s, 3H), 
3.21 (s, 3H), 6.92-7.00 (m, 3H), 7.28-7.32 (m, 2H), 7.51-7.57 (m, 1H), 7.67 (d, J = 5.0 Hz, 
1H), 8.10 (d, J = 5.0 Hz, 1H), 8.15 (s, 1H); 13C NMR (125 MHz, CDCl3) δ: 16.6, 43.3, 
115.9, 120.6, 122.7, 123.3 (q, JCF = 3.7 Hz), 124.1 (q, JCF = 270.0 Hz), 126.2 (q, JCF = 3.7 
Hz), 128.8, 128.9, 129.7, 139.1, 151.2, 162.6; IR (neat) ῡ (cm-1) 3064, 2965, 2877, 1599, 
1492, 1336, 1308, 1265, 1167, 1071, 803; MS (ESI): m/z = 293.4 [M + H+]. 
 1-Methyl-1-phenyl-2-(1-(o-tolyl)ethylidene)hydrazine (4.1y). Yellow oil, yield: 
80% (from ketone). 1H NMR (500 MHz, CDCl3, a mixture of (Z/E) isomers in ratio ca. 5:3, 
the minor one is marked with an *) δ: 2.27 (s, 3H), 2.43 (s, 3H), 3.18 (s, 3H), 6.70-6.84 (m, 
3H), 7.11-7.34 (m, 6H); 2.17* (s, 3H), 2.37* (s, 3H), 2.74* (s, 3H), 6.70-6.84* (m, 3H), 
7.11-7.34* (m, 6H); 13C NMR (125 MHz, CDCl3) δ: 20.3, 20.5, 43.0, 115.9, 120.3, 125.9, 






125.7*, 126.6*, 128.1*, 128.7*, 130.3*, 134.3*, 139.4*, 150.9*, 162.3*; IR (neat) ῡ (cm-
1) 3059, 2960, 2870, 1597, 1493, 1453, 1312, 1094, 752; MS (ESI): m/z = 239.4 [M + H+]. 
 2-(1-(2-Fluorophenyl)ethylidene)-1-methyl-1-phenylhydrazine (4.1z). Yellow 
oil, yield: 89% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.34 (d, J = 5.0 Hz, 3H), 
3.19 (s, 3H), 6.91-6.95 (m, 1H), 6.99-7.00 (m, 2H), 7.09-7.13 (m, 1H), 7.17-7.20 (m, 1H), 
7.28-7.31 (m, 2H), 7.34-7.39 (m, 1H), 7.75-7.79 (m, 1H); 13C NMR (125 MHz, CDCl3) δ: 
19.7 (d, JCF = 5.0 Hz), 42.8, 115.8, 116.1 (d, JCF = 22.5 Hz), 120, 124.2 (d, JCF = 3.7 Hz), 
127.4 (d, JCF = 12.5 Hz), 128.8, 129.6 (d, JCF = 2.5 Hz), 130.8 (d, JCF = 8.7 Hz), 151.1, 
160.7 (d, JCF = 247.5 Hz), 163.9; IR (neat) ῡ (cm-1) 3061, 2966, 2873, 1598, 1581, 1490, 
1450, 1317, 1287, 1095, 1029, 995, 826; MS (ESI): m/z = 243.3 [M + H+]. 
 2-(1-(2,4-Dimethylphenyl)ethylidene)-1-methyl-1-phenylhydrazine (4.1aa). 
Yellow oil, yield: 81% (from ketone). 1H NMR (500 MHz, CDCl3, a mixture of (Z/E) 
isomers in ratio ca. 2:1, the minor one is marked with an *) δ: 2.25 (s, 3H), 2.32 (s, 3H), 
2.42 (s, 3H), 3.15 (s, 3H), 6.87-6.90 (m, 1H), 6.97-7.04 (m, 5H), 7.22-7.28 (m, 2H); 2.12* 
(s, 3H), 2.30* (s, 3H), 2.34* (s, 3H), 2.73* (s, 3H), 6.70-6.84* (m, 3H), 6.97-7.04* (m, 
2H), 7.22-7.28* (m, 3H); 13C NMR (125 MHz, CDCl3) δ: 20.3, 20.6, 21.2, 42.9, 115.8, 
120.2, 126.5, 127.8, 128.9, 131.7, 135.1, 136.9, 138.3, 151.4, 170.0; 19.8*, 20.6*, 25.9*, 
40.6*, 114.4*, 119.4*, 126.4*, 126.5*, 128.7*, 131.1*, 134.2*, 136.5*, 137.8*, 150.9*, 
162.7*; IR (neat) ῡ (cm-1) 3058, 2960, 2869, 1597, 1494, 1451, 1312, 1287, 1094, 1029, 
877; MS (ESI): m/z = 253.4 [M + H+]. 
 1-Methyl-2-(1-(naphthalen-2-yl)ethylidene)-1-phenylhydrazine (4.1ab). 
Yellow solid, yield: 80% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.47 (s, 3H), 3.23 






8.24 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.5, 42.9, 115.6, 120.1, 123.9, 126.3, 126.7, 
126.8, 127.7, 127.9, 128.7, 128.9, 133.1, 134.1, 135.7, 151.4, 164.9; IR (neat) ῡ (cm-1) 
3057, 2962, 2872, 1598, 1491, 1368, 1313, 1234, 1154, 1094, 1066, 859; MS (ESI): m/z = 
275.4 [M + H+]. 
 General procedure for the preparation of N-methyl-N-phenylhydrazones 4.1f, 
4.1l, and 4.1o18 
A 50-mL Schlenk tube was charged with tris(dibenzylideneacetone)dipalladium(0) (4.6 mg, 
0.005 mmol), 1,1′-ferrocenediyl-bis(diphenylphosphine) (5.5 mg, 0.01 mmol), and 
Zn(CN)2 (42.3 mg, 0.36 mmol). Then N-bromophenyl-N-methylhydrazone (91.0 mg, 0.3 
mmol) in DMF (3 mL) was added, and the vial was evacuated and filled with argon. After 
stirring at 120-150 ˚C for 20 h, the reaction mixture was cooled to room temperature, 
diluted with EtOAc (15 mL) and filtered through a pad of Celite. The filtrate was washed 
with water (20 mL x 3) to remove the DMF. The organic phase was dried over Na2SO4, 
concentrated, and the residue was purified by flash chromatography on silica (gradient 
eluent of EtOAc in hexanes: 4 ~ 5%, v/v) to yield the desired product as a yellow oil. 
 4-(1-Methyl-2-(1-phenylethylidene)hydrazinyl)benzonitrile (4.1f). Yellow oil, 
yield: 72% (from 4.1e). 1H NMR (500 MHz, CDCl3) δ: 2.37 (s, 3H), 3.20 (s, 3H), 6.88-
6.91 (m, 2H), 7.41-7.90 (m, 5H), 7.91-7.93 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.7, 
41.0, 100.7, 113.7, 120.2, 126.7, 128.5, 130.5, 133.0, 137.2, 152.9, 168.1; IR (neat) ῡ (cm-
1) 3057, 2920, 2881, 2215, 1603, 1572, 1509, 1464, 1335, 1176, 1098, 828; MS (ESI): m/z 
= 250.2 [M + H+]. 
 3-(1-Methyl-2-(1-phenylethylidene)hydrazinyl)benzonitrile (4.1l). Yellow oil, 






7.15 (m, 2H), 7.20 (s, 1H), 7.31-7.34 (m, 1H), 7.43-7.46 (m, 3H), 7.90-7.92 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ: 16.6, 41.7, 112.6, 117.7, 118.8, 119.5, 122.8, 126.7, 128.5, 
129.5, 130.4, 137.9, 151.3, 167.3; IR (neat) ῡ (cm-1) 3065, 2967, 2878, 2227, 1595, 1576, 
1487, 1444, 1364, 1329, 1293, 1100, 1073, 997; MS (ESI): m/z = 250.2 [M + H+]. 
 2-(1-Methyl-2-(1-phenylethylidene)hydrazinyl)benzonitrile (4.1o). Yellow oil, 
yield: 73% (from ketone). 1H NMR (500 MHz, CDCl3) δ: 2.38 (s, 3H), 3.21 (s, 3H), 7.00-
7.03 (m, 1H), 7.28 (d, J = 5.0 Hz, 1H), 7.39- 7.42 (m, 3H), 7.44-7.47 (m, 1H), 7.57-7.59 
(m, 1H), 7.86-7.88 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 16.9, 44.2, 104.2, 118.1, 118.5, 
121.9, 126.8, 128.4, 130.1, 133.3, 134.5, 137.7, 155.3, 167.6; IR (neat) ῡ (cm-1) 3061, 2965, 
2922, 2877, 2219, 1595, 1445, 1364, 1293, 1064, 760; MS (ESI): m/z = 250.4 [M + H+]. 
 General procedure for the dehydrogenative cyclization recations 
A 50-mL Schlenk tube was charged with N-methyl-N-phenylhydrazones (4, 0.3 mmol), 
CuSO4 (1.0 mg, 0.0045 mmol), CuI (4.2 mg, 0.0225 mmol), Py (84.4 µL, 1.05 mmol), and 
DMF (2.7 mL). Then the solution of CF3SO3H (26.5 µL, 0.3 mmol) in DMF (0.3 mL) was 
slowly added. The vial was evacuated and filled with 1 atm O2, and stirred rigorously at 
95-150 ˚C for 14-48 h. After removal of the solvent, the residue was purified by flash 
chromatography on silica gel (gradient eluent of 5% EtOAc and 1% Et3N in hexanes, v/v) 
to give the desired product as a colorless or pale yellow solid. 
 3-Phenylcinnoline (4.2a). Pale yellow solid (known compound19), yield: 80%. 1H 
NMR (500 MHz, CDCl3) δ: 7.46-7.48 (m, 1H), 7.52-7.55 (m, 2H), 7.68-7.83 (m, 3H), 8.11 
(s, 1H), 8.23 (d, J = 10.0 Hz, 2H), 8.52 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) 






 6-Methyl-3-phenylcinnoline (4.2b). Pale yellow solid, yield: 72%. 1H NMR (500 
MHz, CDCl3) δ: 7.47-7.63 (m, 5H), 8.06 (s, 1H), 8.23 (d, J = 10.0 Hz, 2H), 8.42 (d, J = 5.0 
Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 22.1, 118.2, 125.3, 126.7, 127.2, 129.0, 129.3, 
129.5, 132.8, 137.1, 141.9, 149.0, 153.4; IR (neat) ῡ (cm-1) 3056, 2922, 2852, 1733, 1717, 
1695, 1652, 1558, 1521, 1456, 819; MS (ESI): m/z = 221.3 [M + H+]. 
 6-Fluoro-3-phenylcinnoline (4.2c). Pale yellow solid, yield: 82%. 1H NMR (500 
MHz, CDCl3) δ: 7.44-7.46 (m, 1H), 7.48-7.52 (m, 1H), 7.54-7.59 (m, 3H), 8.11 (s, 1H), 
8.22-8.24 (m, 2H), 8.56-8.59 (m, 1H); 13C NMR (125 MHz, CDCl3) δ: 109.6 (d, JCF = 22.5 
Hz), 118.3 (d, JCF = 6.2 Hz), 121.4 (d, JCF = 27.5 Hz), 127.3, 127.9 (d, JCF = 1.2 Hz), 129.1, 
129.7, 133.2 (d, JCF = 10.0 Hz), 136.5, 147.9, 153.6, 163.1 (d, JCF = 255.0 Hz); IR (neat) ῡ 
(cm-1) 3045, 3019, 1626, 1481, 1455, 1175, 913; MS (ESI): m/z = 225.3 [M + H+]. 
 6-Chloro-3-phenylcinnoline (4.2d). Pale yellow solid, yield: 88%. 1H NMR (500 
MHz, CDCl3) δ: 7.47-7.56 (m, 3H), 7.69-7.71 (m, 1H), 7.81-7.82 (m, 1H), 8.03 (s, 1H), 
8.21 (d, J = 10.0 Hz, 2H), 8.46 (d, J = 5.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 117.5, 
125.5, 127.1, 127.3, 129.1, 129.7, 131.4, 131.5, 136.4, 137.5, 148.1, 153.9; IR (neat) ῡ (cm-
1) 3035, 2923, 1733, 1700, 1684, 1606, 1490, 1295, 1103, 908; MS (ESI): m/z = 242.3 [M 
+ H+]. 
 6-Bromo-3-phenylcinnoline (4.2e). Pale yellow solid, yield: 91%. 1H NMR (500 
MHz, CDCl3) δ: 7.47-7.55 (m, 3H), 7.83 (d, J = 10.0 Hz, 1H), 8.01-8.02 (m, 2H), 8.21 (d, 
J = 10.0 Hz, 2H), 8.38 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 117.3, 126.2, 
127.3, 127.4, 128.9, 129.1, 129.7, 131.4, 133.9, 136.3, 148.2, 153.9; IR (neat) ῡ (cm-1) 






 3-Phenylcinnoline-6-carbonitrile (4.2f). Pale yellow solid, yield: 92%. 1H NMR 
(500 MHz, CDCl3) δ: 7.54-7.63 (m, 3H), 7.94-7.96 (m, 1H), 8.21 (s, 1H), 8.27 (d, J = 5.0 
Hz, 2H), 8.33 (s, 1H), 8.70 (d, J = 5.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 115.1, 
117.9, 118.0, 125.6, 127.4, 129.3, 130.2, 130.3, 131.6, 133.8, 135.9, 148.9, 154.9; IR (neat) 
ῡ (cm-1) 3769, 3669, 1733, 1717, 1652, 1558, 1540, 1506, 1456; MS (ESI): m/z = 232.4[M 
+ H+]. 
 3-Phenyl-6-(trifluoromethyl)cinnoline (4.2g). Pale yellow solid, yield: 95%. 1H 
NMR (500 MHz, CDCl3) δ: 7.49-7.57 (m, 3H), 7.94-7.96 (m, 1H), 8.20-8.24 (m, 4H), 8.67 
(d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 119.0, 123.3 (q, JCF = 271.2 Hz), 
125.4 (q, JCF = 5.0 Hz), 125.5, 125.7 (q, JCF = 3.7 Hz), 127.3, 129.2, 129.9, 131.3, 132.6 
(q, JCF = 32.5 Hz), 136.1, 149.7, 154.5; IR (neat) ῡ (cm-1) 3050, 3035, 1573, 1362, 1265, 
1122, 921; MS (ESI): m/z = 275.3 [M + H+]. 
 7-Methoxy-3-phenylcinnoline (4.2h1) and 5-methoxy-3-phenylcinnoline 
(4.2h2). Pale yellow solid, yield: 78%. 1H NMR (500 MHz, CDCl3, a mixture of isomers 
4.2h1 and 4.2h2 in ratio ca. 5:1, the minor one is marked with an *) δ: 4.02 (s, 3H), 7.36-
7.38 (m, 1H), 7.45-7.49 (m, 1H), 7.52-7.57 (m, 2H), 7.72-7.76 (m, 2H), 8.06 (s, 1H), 8.19-
8.21 (m, 2H); 4.03* (s, 3H), 6.95* (d, J = 10.0 Hz, 1H), 7.45-7.49* (m, 1H), 7.52-7.57* 
(m, 2H), 7.65-7.69* (m, 1H), 8.10* (d, J = 10.0 Hz, 1H), 8.26-8.28* (m, 2H), 8.52* (s, 1H); 
13C NMR (125 MHz, CDCl3) δ: 55.8, 105.7, 118.9, 122.4, 125.7, 126.9, 128.0, 128.9, 129.1, 
137.1, 151.3, 152.6, 160.9; 55.9*, 107.3*, 113.9*, 120.0*, 122.4*, 127.2*, 128.8*, 129.2*, 
130.1*, 131.4*, 150.2*, 153.3*, 154.3*; IR (neat) ῡ (cm-1) 3066, 2936, 2850, 1620, 1577, 






 7-Methyl-3-phenylcinnoline (4.2i1) and 5-methyl-3-phenylcinnoline (4.2i2). 
Pale yellow solid, yield: 62%. 1H NMR (500 MHz, CDCl3, a mixture of isomers 4.2i1 and 
4.2i2 in ratio ca. 2.2:1, the minor one is marked with an *) δ: 2.74 (s, 3H), 7.48-7.52 (m, 
1H), 7.54-7.59 (m, 3H), 7.68-7.71 (m, 1H), 8.23-8.27 (m, 3H), 8.40 (d, J = 5.0 Hz, 1H); 
2.63* (s, 3H), 7.48-7.52* (m, 1H), 7.54- 7.59* (m, 3H), 7.77* (d, J = 10.0 Hz, 1H), 8.23-
8.27* (m, 3H), 8.31* (s, 1H); 13C NMR (125 MHz, CDCl3) δ: 17.8, 115.7, 127.1, 127.9, 
129.0, 129.3, 129.8, 131.1, 133.8, 134.1, 137.3, 150.1, 153.3; 22.0*, 118.6*, 124.7*, 
126.1*, 126.5*, 128.2*, 128.8,* 129.0*, 129.2*, 131.6*, 140.8*, 150.1*, 153.3*; IR (neat) 
ῡ (cm-1) 3059, 2921, 2857, 1733, 1717, 1695, 1615, 1451, 1317, 1110, 892; MS (ESI): m/z 
= 221.3 [M + H+]. 
 7-Bromo-3-phenylcinnoline (4.2j1) and 5-bromo-3-phenylcinnoline (4.2j2). 
Pale yellow solid, yield: 68%. 1H NMR (500 MHz, CDCl3, a mixture of isomers 4.2j1 and 
4.2j2 in ratio ca. 1.7:1, the minor one is marked with an *) δ: 7.51-7.61 (m, 3H), 7.67- 7.70 
(m, 1H), 8.00 (d, J = 5.0 Hz, 1H), 8.29-8.31 (m, 2H), 8.43 (s, 1H), 8.55 (d, J = 5.0 Hz, 1H); 
7.51-7.61* (m, 3H), 7.74-7.81* (m, 2H), 8.13* (s, 1H), 8.23-8.24* (m, 2H), 8.74* (s, 1H); 
13C NMR (125 MHz, CDCl3) δ: 117.7, 127.5, 129.1 (2C), 129.7, 129.8, 130.4, 131.9, 134.4, 
136.5, 150.2, 154.6; 118.4*, 121.2*, 124.0*, 125.1*, 126.5*, 128.0*, 128.4,* 128.5*, 
131.9*, 136.4*, 150.0*, 153.8*; IR (neat) ῡ (cm-1) 3024, 1565, 1438, 1307, 1100, 817; MS 
(ESI): m/z = 286.2 [M + H+]. 
 7-Isopropyl-3-phenylcinnoline (4.2k). Pale yellow solid, yield: 60%. 1H NMR 
(500 MHz, CDCl3) δ: 1.41 (d, J = 5.0 Hz, 6H), 3.16-3.23 (m, 1H), 7.47-7.50 (m, 1H), 7.55-
7.58 (m, 2H), 7.65- 7.67 (m, 1H), 7.81 (d, J = 10.0 Hz, 1H), 8.13 (s, 1H), 8.24 (d, J = 10.0 






126.7, 127.1, 129.0, 129.2, 131.7, 137.1, 150.3, 151.5, 153.1; IR (neat) ῡ (cm-1) 3057, 2961, 
2927, 2870, 1695, 1586, 1577, 1540, 1113, 903; MS (ESI): m/z = 249.3 [M + H+]. 
 3-Phenylcinnoline-7-carbonitrile (4.2l). Pale yellow solid, yield: 73%. 1H NMR 
(500 MHz, CDCl3) δ: 7.55-7.64 (m, 3H), 7.89-7.92 (m, 1 H), 8.19-8.21 (m, 1H), 8.31-8.33 
(m, 2H), 8.45 (s, 1H), 8.84 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 110.1, 
115.4, 115.5, 126.5, 127.6, 129.1, 129.3, 130.4, 135.4, 135.7, 137.6, 148.4, 155.0; IR (neat) 
ῡ (cm-1) 3064, 2924, 1733, 1717, 1684, 1616, 1521, 1313, 1105, 893; MS (ESI): m/z = 
232.4 [M + H+]. 
 8-Methoxy-3-phenylcinnoline (4.2m). Pale yellow solid, yield: 88%. 1H NMR 
(500 MHz, CDCl3) δ: 4.16 (s, 3H), 7.05 (d, J = 10.0 Hz, 1H), 7.37 (d, J = 5.0 Hz, 1H), 
7.46-7.64 (m, 4H), 8.06 (s, 1H), 8.25 (d, J = 5.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ: 
56.2, 107.9, 118.3, 118.4, 127.2, 127.8, 129.0, 129.4, 131.9, 136.9, 142.8, 153.9, 156.2; IR 
(neat) ῡ (cm-1) 3062, 2934, 2848, 1684, 1614, 1551, 1454, 1429, 1390, 1282, 1109; MS 
(ESI): m/z = 237.4 [M + H+]. 
 8-Chloro-3-phenylcinnoline (4.2n). Pale yellow solid, yield: 76%. 1H NMR (500 
MHz, CDCl3) δ: 7.48-7.51 (m, 1H), 7.54-7.57 (m, 2H), 7.61-7.64 (m, 1H), 7.77-7.78 (m, 
1H), 7.84-7.86 (m, 1H), 8.13 (s, 1H), 8.26 (d, J = 10.0 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ: 118.4, 126.2, 127.2, 128.1, 129.1, 129.8, 130.2, 131.2, 134.9, 136.2, 145.9, 154.1; 
IR (neat) ῡ (cm-1) 3063, 2923, 2851, 1698, 1610, 1588, 1111, 989; MS (ESI): m/z = 242.3 
[M + H+]. 
 3-Phenylcinnoline-8-carbonitrile (4.2o). Pale yellow solid, yield: 47%. 1H NMR 
(500 MHz, CDCl3) δ: 7.54-7.62 (m, 3H), 7.82-7.85 (m, 1H), 8.15-8.16 (m, 1H), 8.23-8.25 






118.4, 126.6, 127.4, 129.3, 130.2, 130.3, 132.1, 135.8, 136.6, 147.8, 155.2; IR (neat) ῡ (cm-
1) 2925, 2854, 1733, 1700, 1684, 1646, 1576, 1558, 1512; MS (ESI): m/z = 232.4 [M + 
H+]. 
 3-Phenylbenzo[h]cinnoline (4.2p). Pale yellow solid, yield: 64%. 1H NMR (500 
MHz, CDCl3) δ: 7.49-7.53 (m, 1H), 7.56-7.59 (m, 2H), 7.64 (d, J = 10 Hz, 1H), 7.76-7.79 
(m, 1H), 7.83- 7.86 (m, 1H), 7.90-7.95 (m, 2H), 8.16 (s, 1H), 8.28-8.30 (m, 2H), 9.62 (d, J 
= 10 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 119.4, 123.7, 124.2, 126.4, 127.1, 128.2, 
128.6, 129.1, 129.4, 129.6, 129.9, 133.2, 133.3, 136.8, 147.6, 155.3; IR (neat) ῡ (cm-1) 
3750, 3675, 3058, 2924, 2852, 1772, 1733, 1675, 1646, 1540, 1465, 1441, 1386, 1261, 903, 
805, 771, 753; MS (ESI): m/z = 257.4 [M + H+]. 
 3-(p-Tolyl)cinnoline (4.2q). Pale yellow solid, yield: 61%. 1H NMR (500 MHz, 
CDCl3) δ: 3.87 (s, 3H), 7.04-7.07 (m, 2H), 7.66-7.76 (m, 2H), 7.80 (d, J = 10.0 Hz, 1H), 
8.04 (s, 1H), 8.18-8.21 (m, 2H), 8.50 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 
55.3, 114.4, 117.8, 126.5, 126.8, 128.5, 129.4, 129.7, 129.8, 131.1, 149.6, 153.1, 160.8; IR 
(neat) ῡ (cm-1) 3060, 2936, 2836, 1772, 1700, 1606, 1515, 1438, 1292, 1258, 1175, 1035, 
1020, 832; MS (ESI): m/z = 237.3 [M + H+]. 
 3-(4-Methoxyphenyl)cinnoline (4.2r). Pale yellow solid, yield: 77%. 1H NMR 
(500 MHz, CDCl3) δ: 2.43 (s, 3H), 7.35 (d, J = 5.0 Hz, 2H), 7.68-7.83 (m, 3H), 8.09 (s, 
1H), 8.13 (d, J = 5.0 Hz, 2H), 8.52 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 
21.3, 118.2, 126.5, 126.9, 127.1, 129.7 (2C), 130.0, 131.0, 134.1, 139.5, 149.7, 153.4; IR 
(neat) ῡ (cm-1) 3038, 2916, 2854, 1772, 1739, 1717, 1610, 1540, 1437, 1328, 1183, 1096; 






 3-(4-Fluorophenyl)cinnoline (4.2s). Pale yellow solid, yield: 80%. 1H NMR (500 
MHz, CDCl3) δ: 7.21-7.27 (m, 2H), 7.71-7.75 (m, 1H), 7.79-7.85 (m, 2H), 8.10 (s, 1H), 
8.21-8.23 (m, 2H), 8.53 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 116.1 (d, JCF 
= 21.2 Hz), 118.4, 126.4, 126.9, 129.1 (d, JCF = 8.7 Hz), 129.8, 130.3, 131.4, 133.1 (d, J CF 
= 3.7 Hz), 149.8 (d, JCF = 2.5 Hz), 152.5 (d, JCF = 25.0 Hz), 163.8 (d, JCF = 247.5 Hz); IR 
(neat) ῡ (cm-1) 3057, 2923, 1733, 1717, 1699, 1652, 1588, 1513, 1231, 833; MS (ESI): m/z 
= 225.3 [M + H+]. 
 3-(4-Chlorophenyl)cinnoline (4.2t). Pale yellow solid, yield: 78%. 1H NMR (500 
MHz, CDCl3) δ: 7.50-7.53 (m, 2H), 7.73-7.76 (m, 1H), 7.80-7.86 (m, 2H), 8.12 (s, 1H), 
8.17-8.19 (m, 2H), 8.54 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 118.6, 126.3, 
126.9, 128.4, 129.2, 129.8, 130.4, 131.5, 135.3, 135.7, 149.9, 152.2; IR (neat) ῡ (cm-1) 
3033, 2923, 1736, 1652, 1599, 1558, 1496, 1091; MS (ESI): m/z = 242.3 [M + H+]. 
 3-(4-Bromophenyl)cinnoline (4.2u). Pale yellow solid, yield: 72%. 1H NMR (500 
MHz, CDCl3) δ: 7.65-7.67 (m, 2H), 7.73-7.76 (m, 1H), 7.80-7.86 (m, 2H), 8.10-8.12 (m, 
3H), 8.54 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 118.5, 124.0, 126.3, 126.9, 
128.7, 129.8, 130.5, 131.4, 132.2, 135.8, 149.9, 152.3; IR (neat) ῡ (cm-1) 3035, 2922, 1700, 
1684, 1652, 1593, 1558, 1540, 1495, 826; MS (ESI): m/z = 286.1 [M + H+]. 
 4-(Cinnolin-3-yl)benzonitrile (4.2v). Pale yellow solid, yield: 53%. 1H NMR (500 
MHz, CDCl3) δ: 7.80-7.86 (m, 3H), 7.89-7.94 (m, 2H), 8.25 (s, 1H), 8.39 (d, J = 10.0 Hz, 
2H), 8.60 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 113.0, 118.6, 119.7, 126.1, 
127.1, 127.7, 129.9, 131.2, 131.8, 132.8, 141.1, 150.2, 151.3; IR (neat) ῡ (cm-1) 3744, 3648, 






 3-(m-Tolyl)cinnoline (4.2w). Pale yellow solid, yield: 75%. 1H NMR (500 MHz, 
CDCl3) δ: 2.48 (s, 3H), 7.26-7.30 (m, 1H), 7.42-7.45 (m, 1H), 7.70-7.85 (m, 3H), 8.01 (d, 
J = 5.0 Hz, 1H), 8.09 (s, 1H), 8.13 (s, 1H), 8.54 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ: 21.6, 118.7, 124.5, 126.5, 126.9, 128.0, 128.9, 129.8, 130.1, 130.2, 131.2, 136.8, 
138.7, 149.8, 153.6; IR (neat) ῡ (cm-1) 3055, 2956, 2920, 2853, 1699, 1684, 1617, 1581, 
1495, 1439, 1321, 1178, 1100, 798; MS (ESI): m/z = 221.2 [M + H+]. 
 3-(3-(Trifluoromethyl)phenyl)cinnoline (4.2x). Pale yellow solid, yield: 61%. 1H 
NMR (500 MHz, CDCl3) δ: 7.67-7.80 (m, 3H), 7.84-7.92 (m, 2H), 8.22 (s, 1H), 8.45 (d, J 
= 5.0 Hz, 1H), 8.53 (s, 1H), 8.58 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 
119.1, 124.0 (q, JCF = 3.7 Hz), 124.1 (q, JCF = 271.2 Hz), 126.0 (q, JCF = 3.7 Hz), 126.3, 
127.1, 129.6, 129.9, 130.4, 130.8, 131.4, 131.6, 137.7, 150.1, 151.9; IR (neat) ῡ (cm-1) 
3769, 3758, 1733, 1700, 1646, 1558, 1540, 1456, 1341, 1307, 1112, 1070, 754; MS (ESI): 
m/z = 275.3 [M + H+]. 
 3-(o-Tolyl)cinnoline (4.2y). Pale yellow solid, yield: 90%. 1H NMR (500 MHz, 
CDCl3) δ: 2.44 (s, 3H), 7.33-7.40 (m, 3H), 7.54 (d, J = 5.0 Hz, 1H), 7.73-7.77 (m, 1H), 
7.82-7.86 (m, 2H), 7.90 (s, 1H), 8.58 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ: 
20.5, 122.2, 126.0, 126.1, 126.8, 128.9, 129.8, 130.3, 130.5, 131.0, 131.2, 136.6, 137.6, 
149.3, 156.1; IR (neat) ῡ (cm-1) 3058, 3022, 2957, 2924, 1717, 1603, 1472, 1321, 1241, 
1119, 1092, 967; MS (ESI): m/z = 221.3 [M + H+]. 
 3-(2-Fluorophenyl)cinnoline (4.2z). Colorless solid, yield: 82%. 1H NMR (500 
MHz, CDCl3) δ: 7.22-7.27 (m, 1H), 7.36-7.39 (m, 1H), 7.44-7.48 (m, 1H), 7.74-7.77 (m, 
1H), 7.83-7.88 (m, 2H), 8.34 (s, 1H), 8.41-8.44 (m, 1H), 8.56 (d, J = 10.0 Hz, 1H); 13C 






JCF = 3.7 Hz), 125.0 (d, JCF = 11.2 Hz), 125.9, 127.5 (d, JCF = 15.1 Hz), 127.2, 129.7, 130.6, 
131.0 (d, JCF = 8.7 Hz), 131.3, 131.4 (d, JCF = 2.5 Hz), 149.5 (d, JCF = 25.0 Hz), 160.7 (d, 
JCF = 247.5 Hz); IR (neat) ῡ (cm-1) 3062, 1733, 1717, 1684, 1576, 1569, 1489, 1455, 1204, 
909; MS (ESI): m/z = 225.3 [M + H+]. 
 3-(2,4-Dimethylphenyl)cinnoline (4.2aa). Yellow oil, yield: 96%. 1H NMR (500 
MHz, CDCl3) δ: 2.40 (s, 3 H), 2.42 (s, 3H), 7.15-7.18 (m, 2H), 7.45 (d, J = 10.0 Hz, 1H), 
7.71-7.75 (m, 1H), 7.80-7.84 (m, 2H), 7.87 (s, 1H), 8.56 (d, J = 10.0 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ: 20.5, 21.2, 122.1, 126.1, 126.8, 126.9, 129.7, 130.2, 130.4, 131.1, 
131.2, 134.8, 136.4, 138.7, 149.2, 156.2; IR (neat) ῡ (cm-1) 3035, 3013, 2955, 2920, 2856, 
2925, 1733, 1669, 1615, 1583, 1558, 1472, 1326, 1125, 968; MS (ESI): m/z = 235.4 [M + 
H+]. 
 3-(Naphthalen-2-yl)cinnoline (4.2ab). Pale yellow solid, yield: 67%. 1H NMR 
(500 MHz, CDCl3) δ: 7.49-7.52 (m, 2H), 7.67-7.70 (m, 1H), 7.75-7.78 (m, 1H), 7.81-7.87 
(m, 2H), 7.95-7.98 (m, 2H), 8.20 (s, 1H), 8.31 (d, J = 5.0 Hz, 1H), 8.53 (d, J = 10.0 Hz, 
1H), 8.73 (s, 1H); 13C NMR (125 MHz, CDCl3) δ: 118.8, 124.4, 126.4, 126.5, 126.8 (2C), 
126.9, 127.7, 128.7 (2C), 129.8, 130.2, 131.2, 133.5, 133.7, 134.1, 149.8, 153.2; IR (neat) 
ῡ (cm-1) 3055, 1653, 1617, 1583, 1506, 1470, 1436, 1094, 896; MS (ESI): m/z = 257.3 [M 
+ H+]. 
 Experimental procedure for the transformation of 4.3 to 4.2a 
A 50-mL Schlenk tube was charged with 4.3 (71.4 mg, 0.3 mmol), CuSO4 (1.0 mg, 0.0045 
mmol), CuI (4.2 mg, 0.0225 mmol), pyridine (84.4 µL, 1.05 mmol), and DMF (2.7 mL). 
Then the solution of CF3SO3H (26.5 µL, 0.3 mmol) in DMF (0.3 mL) was slowly added. 






After removal of the solvent, the residue was purified by flash chromatography on silica 
gel (gradient eluent of 5% EtOAc and 1% Et3N in hexanes, v/v) to give 4.2a in 90% yield. 
 2-(2-Methyl-2-phenylhydrazono)-2-phenylacetaldehyde (4.3). Brown solid. 1H 
NMR (500 MHz, CDCl3) δ: 3.15 (s, 3H), 7.09-7.12 (m, 1H), 7.26-7.28 (m, 2H), 7.36-7.42 
(m, 5H), 7.44-7.46 (m, 2H), 9.70 (s, 1H); 13C NMR (125 MHz, CDCl3) δ: 42.1, 117.0, 
123.6, 127.9, 128.6, 129.1, 129.6, 133.2, 141.8, 148.0, 191.7; IR (neat) ῡ (cm-1) 3058, 2731, 
2699, 1693, 1585, 1431, 893; MS (ESI): m/z = 239.4 [M + H+]. 
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CHAPTER 5. RHODIUM-CATALYZED DIRECT SYNTHESIS OF SULFOXIMINES 
FROM SULFOXIDES 
(Reproduced in part with permission from Miao, J.-M.; Richards, N. G. J.; Ge, H.-B. 
“Rhodium-Catalyzed Direct Synthesis of Unprotected NH-Sulfoximines from Sulfoxides”, 






Figure 5.1 Bioactive Sulfoximines 
 Sulfoximines have recently attracted great attention in biochemistry and medicinal 
chemistry because of their versatile chemical properties and diverse bioactivities.1 Since       






 compounds containing a sulfoximine moiety in the pharmacophore have been reported 
(Figure 5.1). For example, compound 5.1 and 5.2 are transition-state-analogue inhibitors 
of L-asparagine synthetase;2 sudexanox (RU31156, 5.3) was selected for clinic studies as 
a prophylactic antiasthmatic;3 sulfoxaflor (5.4) is the first commercially available 
sulfoximine insecticide;4 Bay 1000394 (5.5) is an excellent cyclin-dependent kinase 
inhibitor, which is currently being evaluated in a Phase I clinical trial for activity against 
advanced solid tumors;5 finally, one of the enantiomers of 5.6 shows good anti-proliferative 
activity against various cancer cell lines.6 
 
Scheme 5.1 Preparation of Unprotected NH-Sulfoximines 
 
 Among the small number of synthetic strategies for preparing sulfoximines, the 
most straightforward approach employs direct imination of sulfoxides (Scheme 5.1). 
However, traditional methods require the usage of either toxic or potentially explosive 






sulfonylhydroxylamine (MSH) (eq. 5.1).8 To overcome these drawbacks, considerable 
efforts have been devoted to developing transition metal-catalyzed sulfoxide imination, 
with significant progress being achieved in recent years.9 For example, Tye reported the 
synthesis of sulfoximines by copper-catalyzed imination of sulfoxides with PhI=NNs (Ns 
= para-nitrobenzenesulfonyl) and PhI=NSes (Ses = trimethylsilylethylsulfonyl) (eq. 5.2);9f 
Bolm discovered that this process could be efficiently performed via rhodium9h, silver9i, or 
iron9l,m catalysis using iminoiodinanes generated in-situ from the oxidation of amides by 
PhI(OAc)2 (eq. 5.3).  In spite of this powerful approach, the transition metal-catalyzed 
imination of sulfoxides gives protected sulfoximines, requiring an additional step for 
removal of the undesired protecting group. Inspired by a recent report from Kürti and co-
workers describing the rhodium-catalyzed synthesis of unprotected NH-aziridines from 
olefins using O-(2,4-dinitrophenyl)hydroxylamine (DPH),10 we have developed the first 
transition metal-catalyzed direct synthesis of free NH-sulfoximines from sulfoxides under 
mild conditions (eq. 5.4). 
 
5.2 Results and Discussion 
 Our investigation began with direct imination of phenyl methyl sulfoxide using 1.5 
eq. of O-(2,4-dinitrophenyl)hydroxylamine (DPH) in the presence of 2.5 mol % of 
Rh2(esp)2 at room temperature. After screening a large number of solvents, trifluoroethanol 
(TFE) was found to be optimal, giving the desired free NH-sulfoximine product 5.8a in 61% 
yield (Table 5.1, entry 1). Further screening of Rh(II) catalysts revealed that this process 






Rh(I) did not show catalytic activity in the imination reaction (entry 13).10 Finally, using 
an increased amount of DPH gave an optimal yield for the imination reaction (entry 19). 
Table 5.1 Optimization of Reaction Conditions for Sulfoximinationa 
                
Entry Pd catalyst  Equiv of DPH Solvent Yield (%)b 
1 Rh2(esp)2 1.5 TFE 61 
2 Rh2(esp)2 1.5 MeOH 32 
3 Rh2(esp)2 1.5 MeCN 48 
4 Rh2(esp)2 1.5 nPrCN 44 
5 Rh2(esp)2 1.5 PhCN 42 
6 Rh2(esp)2 1.5 EtOH 30 
7 Rh2(esp)2 1.5 iPrOH 22 
8 Rh2(esp)2 1.5 tBuOH trace 
9 Rh2(esp)2 1.5 HFIP 39 
10 Rh2(esp)2 1.5 DCM 12 
11 Rh2(OAc)4 1.5 TFE 23 
12 Rh2(TFA)4 1.5 TFE trace 
13 Rh(PPh3)3Cl 1.5 TFE 0 
14 Rh2(oct)4 1.5 TFE 0 
15c Rh2(esp)2 1.5 TFE 50 
16d Rh2(esp)2 1.5 TFE 60 
17 Rh2(esp)2 1.0 TFE 48 
18 Rh2(esp)2 2.0 TFE 72 
19 Rh2(esp)2 3.0 TFE 78 
a Reactions were conducted on a 0.3 mmol scale. Conditions: 5.7a (0.3 mmol), Rh 
catalyst (2.5 mol %), DPH (1 -3 equiv), 3 ml solvent, room temperature under N2 
atmosphere, 22 h unless otherwise noted. b  Isolated yields. c 40 ˚C. d 0 ˚C. DPH = O-(2,4-






= 2,2,2-tifluoroethanol. HFIP = hexafluoroisopropanol. The substrate and product are 
racemic mixtures.  
 
Scheme 5.2 Scope of Sulfoxides. Reactions were conducted on a 0.3 mmol scale. 
Conditions: 5.7 (0.3 mmol), Rh2(esp)2 (0.0075 mmol, 2.5 mol%), DPH (0.9 mmol, 3.0 eq.), 
TFE (3 ml, 0.1 M), room temperature, N2 atmosphere, 22 h. The substrates and products 
are racemic mixtures. 
 
 With optimized conditions in hand, we evaluated the generality of the method using 
a variety of sulfoxides as substrates (Scheme 5.2). As expected, functional groups such as 







Not surprisingly, the para-acyl substituted sulfoxide led to a lower yield, perhaps as a result 
of the electron-withdrawing effect of the acyl group acting to decrease the reactivity of 
sulfoxide (5.8e). Furthermore, an apparent steric effect was observed in the imination 
reaction because significantly lower yields were observed with sulfoxides bearing a 
substituent at the ortho position of the phenyl ring (5.8g and 5.8h).  The nature of the aryl 
sulfoxide was not limited, however, to the phenyl ring and naphthanyl. Electron-rich 2-
thiophenyl, and electron-deficient 2-pyridyl methyl sulfoxides were also found to be 
effective substrates for the Rh(II)-catalyzed imination reaction (5.8i-l). On the other hand, 
1-naphthyl and 2-pyridyl methyl sulfoxides provided only modest yields, presumably due 
to steric and electronic factors, respectively (5.8i and 5.8l). In an important observation for 
the preparation of sulfoximine-based small molecules, the methyl group on the phenyl 
methyl sulfoxide could be successfully replaced by other alkyl groups, including the 
cyclopropyl group, to afford the corresponding sulfoximines in high yields (5.8m-p). 
Interestingly, when phenyl allyl sulfoxide was employed in the reaction, selective 
sulfoximination was favoured over aziridination (5.8q).10 
 In addition, diaryl sulfoximines could be effectively prepared with this method 
from the corresponding sulfoxides (5.8r and 5.8s), and we were pleased to find that both 
acyclic and cyclic dialkyl sulfoxides were compatible with this reaction (5.8t and 5.8u). 
 Although the reaction mechanism of this transformation has not been investigated, 
it is likely that a rhodium-nitrene species is an intermediate based on prior literature 
reports.9h,10 Thus, coordination of DPH to Rh2(esp)2, followed by loss of dinitrophenol, 
likely generates a reactive nitrene intermediate, which then oxidizes the metal-coordinated 








 In summary, a novel, efficient, and safe method for the preparation of free NH-
sulfoximines has been developed via rhodium-catalyzed imination of sulfoxides using O-
(2,4-dinitrophenyl)hydroxylamine. This new approach features mild conditions and good 
functional group tolerance, which should permit its application to the synthesis of 
structurally complex sulfoximines with agrochemical and clinical utility.1g 
 
5.4 Experimental 
 General Methods. All the solvents and commercially available reagents were 
purchased from commercial sources and used directly. For TLC analysis, precoated plates 
(w/h F254, Dynamic Adsorbents Inc, 0.25 mm thick) were used; for air-flashed column 
chromatography, Flash Silica Gel (Dynamic Adsorbents Inc, 32-63 μm) was used. The 1H 
and 13C NMR spectra were obtained on a Bruker 500 MHz NMR Fourier transform 
spectrometer. 1H NMR data was reported as: chemical shift (δ ppm), multiplicity, coupling 
constant (Hz), and integration. 13C NMR data was reported in terms of chemical shift (δ 
ppm), multiplicity, and coupling constant (Hz). The infrared spectra were obtained using a 
Thermo Nicolet IR 330 Spectrometer. Mass (MS) analysis was obtained using Agilent 
1100 series LC/MSD system with Electrospray Ionization (ESI). O-(2,4-
Dinitrophenyl)hydroxylamine (DPH) was purchased from Matrix Sci. and used directly. 
 Preparation of Starting Materials (Scheme 5.3): 
Sulfoxides 5.7a, 5.7b, 5.7p, 5.7r, 5.7s, 5.7t, and 5.7u were purchased from Sigma-Aldrich, 
TCI, Alfa Aesar, or MP Biomedicals. 5.7c, 5.7d, 5.7e, 5.7f, 5.7g, 5.7h, 5.7i, 5.7j, 5.7l, 







addition of alkyl bromides or iodides,12 followed by the oxidation with t-BuOOH according 
to the reported procedure.13 5.7k was prepared by the oxidation of the corresponding 
sulfide based on the reported protocol. 
Scheme 5.3 Starting Materials for Racemic Sulfoximination 
 
 General procedure for the imination of sulfoxides. An oven-dried schlenk flask 
was charged with Rh2(esp)2 (11.4 mg, 0.015 mmol) and DPH (0.9 mmol),  and then a 
solution of sulfoxide (5.7, 0.3 mmol) in CF3CH2OH  was added under nitrogen flow. The 
reaction mixture was stirred at 0 ˚C for 2 h under nitrogen, and then warmed to room 
temperature and stirred for another 20 h. The reaction mixture was diluted with EtOAc, 







purified by flash chromatography on silica gel (hexane/EtOAc 4:1~1:2, v/v) to yield the 
desired product 5.8. 
 S-Methyl-S-phenylsulfoximine (5.8a, racemic, known compound14). Yellow oil, 
yield: 78%. 1H NMR (500 MHz, CDCl3) δ: 2.69 (br s, 1 H), 3.08 (s, 3H), 7.51-7.56 (m, 
2H), 7.57-7.62 (m, 1H), 7.97-8.01 (m, 2H). 13C NMR (125 MHz, CDCl3) δ: 46.5, 127.9, 
129.5, 133.3, 143.9. MS (ESI): m/z = 156.1, [M + H+]. 
 S-Methyl-S-(4-methylphenyl)sulfoximine (5.8b, racemic). Yellow oil, yield: 
84%. 1H NMR (500 MHz, CDCl3) δ: 2.42 (s, 3H), 2.50 (br s, 1H), 3.06 (s, 3H), 7.32 (d, J 
= 8.0 Hz, 2H), 7.86 (d, J = 8.0 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 21.8, 46.6, 128.0, 
130.1, 140.9, 144.2. IR (neat) ῡ (cm-1) 3271, 3060, 3025, 2926, 1539, 1455, 1409, 1224, 
1097, 1004, 1027, 799, 750, 625, 525; MS (ESI): m/z = 170.1, [M + H+]. 
 S-Methyl-S-(4-chlorophenyl)sulfoximine (5.8c, racemic). Yellow oil, yield: 90%. 
1H NMR (500 MHz, CDCl3) δ: 2.72 (br s, 1H), 3.09 (s, 3H), 7.51 (d, J = 8.5 Hz, 2H), 7.94 
(d, J = 8.5 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 46.6, 129.6, 129.9, 140.1, 142.5. IR 
(neat) ῡ (cm-1) 3269, 3086, 3019, 2926, 1580, 1470, 1409, 1393, 1321, 1225, 1085, 1002, 
829, 762, 731, 557, 519; MS (ESI): m/z = 190.0, [M + H+]. 
 S-Methyl-S-(4-bromophenyl)sulfoximine (5.8d, racemic). Yellow oil, yield: 86%. 
1H NMR (500 MHz, CDCl3) δ: 2.71 (br s, 1H), 3.07 (s, 3H), 7.67 (d, J = 8.5 Hz, 2H), 7.85 
(d, J = 8.5 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 46.5, 128.5, 129.6, 132.8, 142.9. IR 
(neat) ῡ (cm-1) 3268, 3084, 3015, 2926, 2853, 1572, 1472, 1387, 1321, 1225, 1093, 1066, 
999, 823, 760, 717; MS (ESI): m/z = 234.0, 236.0, [M + H+]. 
 S-Methyl-S-(4-acetylphenyl)sulfoximine (5.8e, racemic). Yellow solid, yield: 







8.08 (d, J = 8.5 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 27.1, 44.1, 124.0, 129.4, 139.4, 
151.3, 197.3. IR (neat) ῡ (cm-1) 3084, 2990, 2912, 2851, 1675, 1425, 1396, 1362, 1295, 
1269, 1092, 1047, 959, 828, 596; MS (ESI): m/z = 198.1, [M + H+]. 
 S-Methyl-S-(3-methylphenyl)sulfoximine (5.8f, racemic). Yellow oil, yield: 88%. 
1H NMR (500 MHz, CDCl3) δ: 2.23-2.67 (br s, 1H), 2.45 (s, 3H), 3.08 (s, 3H), 7.38-7.44 
(m, 2H), 7.76-7.82 (m, 2H). 13C NMR (125 MHz, CDCl3) δ: 21.6, 46.5, 125.1, 128.3, 129.4, 
134.1, 139.8, 143.7. IR (neat) ῡ (cm-1) 3271, 3061, 3021, 2925, 1599, 1477, 1411, 1321, 
1226, 1094, 1019, 993, 792, 750, 687; MS (ESI): m/z = 170.1, [M + H+]. 
 S-Methyl-S-(2-methylphenyl)sulfoximine (5.8g, racemic). Yellow oil, yield: 
36%. 1H NMR (500 MHz, CDCl3) δ: 2.71-2.77 (br s, 1H), 2.76 (s, 3H), 3.13 (s, 3H), 7.28-
7.37 (m, 2H), 7.44-7.50 (m, 1H), 8.09 (d, J = 7.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ: 
21.1, 44.9, 127.0, 129.7, 133.2, 133.3, 137.8, 142.0. IR (neat) ῡ (cm-1) 3272, 3059, 3015, 
2928, 2854, 1470, 1456, 1410, 1319, 1274, 1222, 1195, 1069, 1003, 768, 747; MS (ESI): 
m/z = 170.1, [M + H+]. 
 S-Methyl-S-(2-chlorophenyl)sulfoximine (5.8h, racemic). Yellow oil, yield: 32%. 
1H NMR (500 MHz, CDCl3) δ: 2.91 (br s, 1H), 3.30 (s, 3H), 7.42-7.47 (m, 1H), 7.49-7.55 
(m, 2H), 8.17 (d, J = 7.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ: 43.8, 127.7, 131.0, 132.4, 
132.7, 134.3, 141.3. IR (neat) ῡ (cm-1) 3273, 3084, 3008, 2928, 2853, 1576, 1450, 1431, 
1319, 1231, 1118, 1050, 1003, 959, 755; MS (ESI): m/z = 190.0, [M + H+]. 
 S-Methyl-S-(naphth-2-yl)sulfoximine (5.8i, racemic). Yellow solid, yield: 38%. 
1H NMR (500 MHz, CDCl3) δ: 2.98 (br s, 1H), 3.28 (s, 3H), 7.56-7.64 (m, 2H), 7.67-7.72 
(m, 1H), 7.97 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.38 (dd, J = 1.0, 8.0 Hz, 1H), 







129.3, 129.6, 130.0, 134.8, 134.9, 139.0. IR (neat) ῡ (cm-1) 3272, 3059, 3010, 2927, 2854, 
1592, 1506, 1225, 1019, 952, 807, 772, 750; MS (ESI): m/z = 206.1, [M + H+]. 
 S-Methyl-S-(naphth-1-yl)sulfoximine (5.8j, racemic). Yellow solid, yield: 70%. 
1H NMR (500 MHz, CDCl3) δ: 2.79 (br s, 1H), 3.16 (s, 3H), 7.58-7.67 (m, 2H), 7.92 (d, J 
= 8.5 Hz, 1H), 7.94-8.00 (m, 3H), 8.56 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 46.5, 123.2, 
127.9, 128.2, 129.3 (2C), 129.6, 129.9, 132.6, 135.3, 140.7. IR (neat) ῡ (cm-1) 3264, 3050, 
3034, 3014, 2931, 1584, 1407, 1343, 1324, 1222, 1123, 1076, 1004, 948, 823, 760, 631; 
MS (ESI): m/z = 206.1, [M + H+]. 
 S-Methyl-S-(thiophen-2-yl)sulfoximine (5.8k, racemic). Yellow oil, yield: 75%. 
1H NMR (500 MHz, CDCl3) δ: 3.10 (br s, 1H), 3.23 (s, 3H), 7.08-7.12 (m, 1H), 7.63-7.67 
(m, 2H). 13C NMR (125 MHz, CDCl3) δ: 47.9, 128.2, 133.5, 133.8, 146.3. IR (neat) ῡ (cm-
1) 3267, 3091, 3021, 2926, 1506, 1404, 1342, 1321, 1225, 1096, 1024, 994, 854, 731, 568; 
MS (ESI): m/z = 162.0, [M + H+]. 
 S-Methyl-S-(pyridin-2-yl)sulfoximine (5.8l, racemic). Yellow oil, yield: 56%. 1H 
NMR (500 MHz, CDCl3) δ: 2.84 (br s, 1H), 3.26 (s, 3H), 7.48-7.53 (m, 1H), 7.91-7.97 (m, 
1H), 8.13 (d, J = 8.0 Hz, 1H), 8.73 (d, J = 4.5 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ: 
42.7, 121.4, 127.0, 138.6, 150.4, 161.0. IR (neat) ῡ (cm-1) 3262, 3013, 2925, 2853, 1655, 
1578, 1454, 1426, 1317, 1223, 1136, 1068, 1014, 991, 783, 756, 511; MS (ESI): m/z = 
157.0, [M + H+]. 
 S-Ethyl-S-phenylsulfoximine (5.8m, racemic). Yellow oil, yield: 90%. 1H NMR 
(500 MHz, CDCl3) δ: 1.21-1.26 (m, 3H), 2.61 (br s, 1H), 3.15 (q, J = 7.5 Hz, 2H), 7.50-
7.56 (m, 2H), 7.57-7.63 (m, 1H), 7.95 (d, J = 8.0 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 







1647, 1583, 1477, 1446, 1409, 1380, 1231, 1201, 1098, 973, 761, 721, 691, 674, 568, 510; 
MS (ESI): m/z = 170.1, [M + H+]. 
 S-Propyl-S-phenylsulfoximine (5.8n, racemic). Yellow solid, yield: 94%. 1H 
NMR (500 MHz, CDCl3) δ: 0.94 (t, J = 7.5 Hz, 3H), 1.59-1.80 (m, 2H), 2.58 (br s, 1H), 
3.03-3.15 (m, 2H), 7.49-7.54 (m, 2 H), 7.56-7.61 (m, 1H), 7.94 (d, J = 7.5 Hz, 2H). 13C 
NMR (125 MHz, CDCl3) δ: 13.1, 17.2, 59.5, 128.7, 129.4, 133.3, 142.4. IR (neat) ῡ (cm-1) 
3268, 3063, 2969, 2935, 2877, 1701, 1446, 1406, 1224, 1100, 985, 754, 690, 572, 544, 510; 
MS (ESI): m/z = 184.1, [M + H+]. 
 S-Isopropyl-S-phenylsulfoximine (5.8o, racemic). Yellow solid, yield: 92%. 1H 
NMR (500 MHz, CDCl3) δ: 1.21-1.34 (m, 6H), 2.41 (br s, 1H), 3.19-3.29 (m, 1H), 7.50-
7.56 (m, 2H), 7.58-7.63 (m, 1H), 7.94 (d, J = 7.5 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 
16.3, 16.7, 56.8, 129.3, 129.7, 133.3, 140.2. IR (neat) ῡ (cm-1) 3270, 3063, 2975, 2929, 
2872, 1666, 1467, 1445, 1385, 1366, 1261, 1214, 1105, 978, 759, 716, 692, 650, 565, 548; 
MS (ESI): m/z = 184.1, [M + H+]. 
 S-Cyclopropyl-S-phenylsulfoximine (5.8p, racemic). Yellow oil, yield: 80%. 1H 
NMR (500 MHz, CDCl3) δ: 0.85-0.94 (m, 1 H), 0.99-1.07 (m, 1H), 1.13-1.21 (m, 1H), 
1.33-1.41 (m, 1H), 2.32-2.62 (m, 2H), 7.49-7.55 (m, 2H), 7.56-7.61 (m, 1H), 7.95 (d, J = 
7.5 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ: 5.9, 6.3, 34.5, 128.1, 129.4, 133.0, 143.5. IR 
(neat) ῡ (cm-1) 3267, 3060, 3015, 2924, 2853, 1477, 1445, 1418, 1305, 1224, 1188, 1096, 
984, 884, 827, 758, 718, 690, 562, 525; MS (ESI): m/z = 182.1, [M + H+]. 
 S-Allyl-S-phenylsulfoximine (5.8q, racemic). Yellow oil, yield: 76%. 1H NMR 
(500 MHz, CDCl3) δ: 2.84 (br s, 1H), 3.78-3.90 (m, 2H), 5.13 (d, J = 17.0 Hz, 1H), 5.33 







13C NMR (125 MHz, CDCl3) δ: 62.8, 124.7, 125.7, 129.1, 129.3, 133.5, 141.2. MS (ESI): 
m/z = 182.1, [M + H+]. 
 S,S-Diphenylsulfoximine (5.8r, racemic). Yellow solid, yield: 90%. 1H NMR (500 
MHz, CDCl3) δ: 3.07 (br s, 1H), 7.42-7.52 (m, 6H), 8.03 (d, J = 7.5 Hz, 4H). 13C NMR 
(125 MHz, CDCl3) δ: 128.1, 129.4, 132.8, 143.6. IR (neat) ῡ (cm-1) 3269, 3062, 3003, 2923, 
1583, 1476, 1447, 1230, 1129, 1094, 1069, 980, 760, 721, 688, 569, 542; MS (ESI): m/z = 
218.1, [M + H+]. 
 S,S-Di(4-methyl-phenyl)sulfoximine (5.8s, racemic). Yellow solid, yield: 84%. 
1H NMR (500 MHz, CDCl3) δ: 2.37 (s, 6H), 2.97 (br s , 1H), 7.26 (d, J = 8.0 Hz, 4H), 7.91 
(d, J = 8.0 Hz, 4H). 13C NMR (125 MHz, CDCl3) δ: 21.8, 128.2, 130.1, 141.1, 143.6. IR 
(neat) ῡ (cm-1) 3272, 3060, 3027, 2956, 2923, 2855, 720, 1596, 1491, 1450, 1401, 1380, 
1228, 1130, 1095, 1019, 977, 818, 662, 623, 541; MS (ESI): m/z = 246.1, [M + H+]. 
 S,S-Dibenzylsulfoximine (5.8t, racemic). Yellow solid, yield: 74%. 1H NMR (500 
MHz, CDCl3) δ: 4.17 (d, J = 8.0 Hz, 2H), 4.28 (d, J = 8.0 Hz, 2H), 7.39-7.42 (m, 5H). 13C 
NMR (125 MHz, CDCl3) δ: 60.8, 128.2, 129.2, 129.3, 131.4. IR (neat) ῡ (cm-1) 3250, 3086, 
3064, 3030, 2976, 2919, 1493, 1455, 1417, 1259, 1246, 1156, 1150, 1073, 1039, 776, 697, 
586; MS (ESI): m/z = 246.1, [M + H+]. 
 S,S-Tetramethylenesulfoximine (5.8u, racemic). Yellow oil, yield: 70%. 1H NMR 
(500 MHz, CDCl3) δ: 2.19-2.29 (m, 4H), 2.75 (br s, 1H), 3.06-3.16 (m 4H). 13C NMR (125 
MHz, CDCl3) δ: 24.3, 55.7. IR (neat) ῡ (cm-1) 3386, 3262, 2951, 2926, 2876, 2854, 1654, 
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Figure A 1 Crystallographic Structure of L-2.2g 
 
Table A 1 Crystallographic Data and Structure Refinement for L-2.2g 
Identification code b 
Empirical formula                  C25 H22 F N3 O3  
Formula weight                    431.46  
Temperature     293(2) K 
Wavelength                       0.71073 A 
Crystal system, space group          Monoclinic,  P21/N  
Unit cell dimensions                a = 11.943(2) A   alpha = 90 deg.  
b = 12.618(3) A    beta = 90.20(3) deg. 
c = 14.512(3) A   gamma = 90 deg. 
Volume 2186.9(8) A^3 
Z, Calculated density               4, 1.310 Mg/m^3 
Absorption coefficient              0.093 mm^-1 
      F(000)                           904 
Crystal size                       0.30 x 0.20 x 0.10 mm 
Theta range for data collection        2.14 to 25.42 deg. 
      Limiting indices                   0<=h<=14, 0<=k<=15, -17<=l<=17 
Reflections collected / unique         
Completeness to theta = 25.42        99.7 % 
Absorption correction               Psi-scan 
Max. and min. transmission          0.9907 and 0.9726 
Refinement method                Full-matrix least-squares on F^2 
Data / restraints / parameters         4026 / 0 / 289 
Goodness-of-fit on F^2             1.006 
Final R indices [I>2sigma(I)]        R1 = 0.0676, wR2 = 0.1345 
R indices (all data)                 R1 = 0.1521, wR2 = 0.1626 







Appendix B NOESY Spectra of 3.2f 
 
H1-H4 and H1-H6 correlations were observed. 
H1-H3 correlation was not observed. 
 







Appendix C HPLC Data for 3.1g and 3.2g 
Chiral Stationary phase: Chiralpak ® AD-H, n-hexane/isopropanol = 92:8, 0.70 mL/min  
Signal: VWD1 A, Wavelength=210 nm. 
 
 
Figure C 1 HPLC Spectra of D,L-3.1g 
 
Table C 1 HPLC Data for D,L-3.1g 
Retention Time Area Area% 
48.277 87030121 49.70 












Figure C 2 HPLC Spectra of D-3.1g 
 
Table C 2 HPLC Data for D-3.1g 
Retention Time Area Area% 
50.277                          1569630        1.01 














Chiral Stationary phase: Chiralpak ® AD-H, n-hexane/isopropanol = 75:25, 1.00 mL/min  




Figure C 3 HPLC Spectra of D,L-3.2g 
 
Table C 3 HPLC Data for D,L-3.2g 
Retention Time Area Area% 
8.288            15865404 50.12     














Figure C 4 HPLC Spectra of D-3.2g 
 
Table C 4 HPLC Data for D-3.2g 
Retention Time Area Area% 
8.261                         20995719         98.76 
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